[{"Link/DOI": "https://doi.org/10.26434/chemrxiv-2024-d0bwc", "Publication Date": "2024-03-12 00:00:00", "Title": "photodynamic treatment of staphylococcus aureus with non-iron hemin analogs in the presence of hydrogen peroxide", "ID Score": "0.9999888", "Team Score": "0.8044094", "Authors": "Badhu Sivasubramaniam Benjamin Washer Yuichiro Watanabe Kathryn Ragheb J. Paul Robinson Alexander Wei", "Abstract": "photodynamic treatment of staphylococcus aureus with non-iron hemin analogs in the presence of hydrogen peroxide acteria subjected to antiseptic or antibiotic stress often develop tolerance, a trait that can lead to permanent resistance. to determine whether photodynamic agents could be used to counter tolerance, we evaluated three non-iron hemin analogs (m-ppix; m = al, ga, in) as targeted photosensitizers for antimicrobial photodynamic inactivation (apdi) following exposure to sublethal h2o2. al-ppix is an active producer of ros whereas ga- and in-ppix are more efficient at generating singlet oxygen. al- and ga-ppix are highly potent apdi agents against s. aureus and methicillin-resistant strains (mrsa) with antimicrobial activity (3-log reduction in colony-forming units) at nanomolar concentrations. the apdi activities of al- and ga-ppix against s. aureus were tested in the presence of 1 mm h2o2 added at different stages of growth. bacteria exposed to h2o2 during log-phase growth were less susceptible to apdi but bacteria treated with h2o2 in their postgrowth phase exhibited apdi hypersensitivity, with 6-log reduction (eradication) using only 15 nm ga-ppix."}, {"Link/DOI": "https://doi.org/10.1101/2022.12.18.22283646", "Publication Date": "2024-02-10 00:00:00", "Title": "association between sars-cov-2 infection and select symptoms and conditions 31 to 150 days after testing among children and adults", "ID Score": "0.9999893", "Team Score": "0.9728822", "Authors": "['Zhang, Y.; Romieu-Hernandez, A.; Boehmer, T. K.; Azziz-Baumgartner, E.; Carton, T.; Gundlapalli, A. V.; Fearrington, J.; Nagavedu, K.; Dea, K.; Moyneur, E.; Cowell, L. G.; Kaushal, R.; Mayer, K. H.; Puro, J.; Rasmussen, S. A.; Thacker, D.; Weiner, M. G.; Saydeh, S.; Block, J. P.']", "Abstract": "backgroundan increasing number of studies have described new and persistent symptoms and conditions as potential post-acute sequelae of sars-cov-2 infection (pasc). however, it remains unclear whether certain symptoms or conditions occur more frequently among persons with sars-cov-2 infection compared with those never infected with sars-cov-2. we compared the occurrence of specific covid-associated symptoms and conditions as potential pasc 31 to 150 days following a sars-cov-2 test among adults ([&ge;]20 years) and children (<20 years) with positive and negative test results documented in the electronic health records (ehrs) of institutions participating in pcornet, the national patient-centered clinical research network.  methods and findingsthis study included 3,091,580 adults (316,249 sars-cov-2 positive; 2,775,331 negative) and 675,643 children (62,131 positive; 613,512 negative) who had a sars-cov-2 laboratory test (nucleic acid amplification or rapid antigen) during march 1, 2020-may 31, 2021 documented in their ehr. we identified hospitalization status in the day prior through the 16 days following the sars-cov-2 test as a proxy for the severity of covid-19. we used logistic regression to calculate the odds of receiving a diagnostic code for each symptom outcome and cox proportional hazard models to calculate the risk of being newly diagnosed with each condition outcome, comparing those with a sars-cov-2 positive test to those with a negative test. after adjustment for baseline covariates, hospitalized adults and children with a positive test had increased odds of being diagnosed with [&ge;]1 symptom (adults: adjusted odds ratio[aor], 1.17[95% ci, 1.11-1.23]; children: aor, 1.18[95% ci, 1.08-1.28]) and shortness of breath (adults: aor, 1.50[95% ci, 1.38-1.63]; children: aor, 1.40[95% ci, 1.15-1.70]) 31-150 days following a sars-cov-2 test compared with hospitalized individuals with a negative test. hospitalized adults with a positive test also had increased odds of being diagnosed with [&ge;]3 symptoms (aor, 1.16[95% ci, 1.08 - 1.26]) and fatigue (aor, 1.12[95% ci, 1.05 - 1.18]) compared with those testing negative. the risks of being newly diagnosed with type 1 or type 2 diabetes (ahr, 1.25[95% ci, 1.17-1.33]), hematologic disorders (ahr, 1.19[95% ci, 1.11-1.28]), and respiratory disease (ahr, 1.44[95% ci, 1.30-1.60]) were higher among hospitalized adults with a positive test compared with those with a negative test. non-hospitalized adults with a positive sars-cov-2 test had higher odds of being diagnosed with fatigue (aor, 1.11[95% ci, 1.05-1.16]) and shortness of breath (aor, 1.22[95% ci, 1.15-1.29]), and had an increased risk (ahr, 1.12[95% ci, 1.02-1.23]) of being newly diagnosed with hematologic disorders (i.e., venous thromboembolism and pulmonary embolism) 31-150 days following sars-cov-2 test compared with those testing negative. the risk of being newly diagnosed with certain conditions, such as mental health conditions and neurological disorders, was lower among patients with a positive viral test relative to those with a negative viral test.  conclusionspatients with sars-cov-2 infection were at higher risk of being diagnosed with certain symptoms and conditions, particularly fatigue, respiratory symptoms, and hematological abnormalities, after acute infection. the risk was highest among adults hospitalized after sars-cov-2 infection."}, {"Link/DOI": "https://doi.org/10.1101/2023.10.24.563688", "Publication Date": "2024-02-09 00:00:00", "Title": "discovery of cmx990: a potent sars-cov-2 3cl protease inhibitor bearing a novel covalent warhead", "ID Score": "0.9999896", "Team Score": "0.98115486", "Authors": "['Elshan, N. G. R. D.; Wolff, K. C.; Riva, L.; Woods, A. K.; Grabovyi, G.; Wilson, K.; Rahimi, A.; Pedroarena, J.; Ghorai, S.; Gupta, A. K.; Nazarian, A.; Weiss, F.; Liu, Y.; Mazumdar, W.; Song, L.; Okwor, N.; Malvin, J.; Bakowski, M. A.; Beutler, N.; Kirkpatrick, M. G.; Gebara-Lamb, A.; Huang, E.; Nguyen-Tran, V.; Chi, V.; Li, S.; Rogers, T. F.; McNamara, C. W.; Chen, J. J.; Joseph, S. B.; Schultz, P. G.; Chatterjee, A. K.']", "Abstract": "there remains a need to develop novel sars-cov-2 therapeutic options that improve upon existing therapies by increased robustness of response, fewer safety liabilities, and global-ready accessibility. functionally critical viral main protease (mpro, 3clpro) of sars-cov-2 is an attractive target due to its homology within the coronaviral family, and lack thereof towards human proteases. in this disclosure, we outline the advent of a novel sars-cov-2 3clpro inhibitor, cmx990, bearing an unprecedented trifluoromethoxymethyl ketone warhead. compared with the marketed drug nirmatrelvir (combination with ritonavir = paxlovidtm), cmx990 has distinctly differentiated potency ([~]5x more potent in primary cells) and human in vitro clearance (>4x better microsomal clearance and >10x better hepatocyte clearance), with good in vitro-in vivo correlation. based on its compelling preclinical profile and projected once or twice a day dosing supporting unboosted oral therapy in humans, cmx990 advanced to a phase 1 clinical trial as an oral drug candidate for sars-cov-2."}, {"Link/DOI": "https://doi.org/10.1101/2023.07.11.23292264", "Publication Date": "2024-02-09 00:00:00", "Title": "efficacy and safety of 5-day oral ensitrelvir for patients with mild-to-moderate covid-19: the scorpio-sr randomized clinical trial", "ID Score": "0.9999896", "Team Score": "0.9933207", "Authors": "['Yotsuyanagi, H.; Ohmagari, N.; Doi, Y.; Yamato, M.; Nguyen, H. B.; Bong, K. C.; Imamura, T.; Sonoyama, T.; Ichihashi, G.; Sanaki, T.; Tsuge, Y.; Uehara, T.; Mukae, H.']", "Abstract": "importancetreatment options for coronavirus disease 2019 (covid-19) that can be used irrespective of risk factors for severe disease are warranted.  objectiveto assess the efficacy and safety of ensitrelvir in patients with mild-to-moderate covid-19.  designthe phase 3 part of a phase 2/3, double-blind, randomized, placebo-controlled study conducted from february 10 to july 10, 2022.  settinga multicenter study conducted at 92 institutions in japan, vietnam, and south korea.  participantspatients (aged 12 to <70 years) with mild-to-moderate covid-19 within 120 hours of positive viral testing.  interventionspatients were randomized (1:1:1) to receive once-daily ensitrelvir 125 mg (375 mg on day 1), 250 mg (750 mg on day 1), or placebo for 5 days. among 1821 randomized patients, 1030 (347, 340, and 343 in the ensitrelvir 125-mg, ensitrelvir 250-mg, and placebo groups, respectively) were randomized in less than 72 hours of disease onset and assessed as the primary analysis population.  main outcomes and measuresthe primary end point was the time to resolution of five covid-19 symptoms (stuffy or runny nose, sore throat, cough, feeling hot or feverish, and low energy or tiredness). other end points included virologic efficacy and safety.  resultsthe mean age was 35.7, 35.3, and 34.7 years, and 193 (55.6%), 185 (54.4%), and 174 (50.7%) patients were men in the ensitrelvir 125-mg, ensitrelvir 250-mg, and placebo groups, respectively (intention-to-treat, primary analysis population). a significant difference (p=.04 with a peto-prentice generalized wilcoxon test stratified by vaccination history) was observed in the primary end point between ensitrelvir 125 mg and placebo in the primary analysis population (difference in median, -24.3 hours; 95% confidence interval, -78.7 to 11.7). viral rna levels on day 4 and time to negative viral titer demonstrated significant reduction vs placebo. the incidence of adverse events was 44.2%, 53.6%, and 24.8% in the ensitrelvir 125-mg, ensitrelvir 250-mg, and placebo groups, respectively. no treatment-related serious adverse events were reported.  conclusions and relevancetreatment with ensitrelvir 125 mg demonstrated clinical and antiviral efficacy without new safety concerns. generalizability to non-asian populations should be confirmed.  trial registrationjapan registry of clinical trials identifier: jrct2031210350.  key pointso_st_absquestionc_st_abscan ensitrelvir, an oral severe acute respiratory syndrome coronavirus 2 3c-like protease inhibitor, shorten the duration of symptoms in patients with mild-to-moderate covid-19 irrespective of risk factors for severe disease?  findingsin this phase 3 part of a phase 2/3, double-blind, randomized study scorpio-sr, a statistically significant difference was observed in the time to resolution of five covid-19 symptoms between ensitrelvir 125 mg and placebo in patients randomized in less than 72 hours of disease onset. viral rna and viral titer demonstrated significant reduction vs placebo.  meaningensitrelvir 125 mg treatment shortened time to resolution of key covid-19 symptoms."}, {"Link/DOI": "https://doi.org/10.1101/2023.09.01.555992", "Publication Date": "2024-02-08 00:00:00", "Title": "therapeutic mitigation of measles-like immune amnesia and exacerbated disease after prior respiratory virus infections in ferrets", "ID Score": "0.9999896", "Team Score": "0.94183916", "Authors": "['Plemper, R. K.; Cox, R.; Wolf, J. D.; Lieberman, N. A. P.; Lieber, C. M.; Kang, H.-J.; Sticher, Z. M.; Yoon, J.-J.; Andrews, M. K.; Govindarajan, M.; Krueger, R. E.; Sobolik, E. B.; Natchus, M. G.; Gewirtz, A.; deSwart, R.; Kolykhalov, A.; Hekmatyar, K.; Sakamoto, K.; Greninger, A. L.']", "Abstract": "after years of the covid-19 pandemic, over 40 million children worldwide are at risk of measles due to delayed vaccination1 and temporary sars-cov-2 viral dominance2. acute measles has a case-fatality rate of [~]1%, but most morbidity and mortality arise post-measles due to destruction of pre-existing immune memory by lymphotropic measles virus (mev)3,4, a paramyxovirus of the morbillivirus genus. mev-induced immune amnesia is not mitigated by post-exposure vaccination and the impact of unrelated respiratory virus disease history on measles severity has not been defined. we used a lethal canine distemper virus (cdv)-ferret model as surrogate for human morbillivirus disease5 and employed the orally efficacious broad-spectrum paramyxovirus polymerase inhibitor ghp-883096 to establish measles treatment paradigms. applying a receptor tropism-intact recombinant cdv with low lethality, we provide in vivo confirmation of the morbillivirus immune amnesia hypothesis and reveal an 8-day advantage of antiviral treatment versus therapeutic vaccination in preserving immune memory. infection of ferrets with non-lethal influenza a virus (iav) a/ca/07/2009 (h1n1) or respiratory syncytial virus (rsv) four weeks prior to cdv caused exacerbated cdv disease that rapidly advanced to fatal hemorrhagic pneumonia associated with lung onslaught by commensal bacteria. rnaseq of bal samples and lung tissue identified cdv-induced expression of trefoil factor (tff) peptides, which was absent in animals pre-infected with iav, thus highlighting that immune priming by unrelated respiratory viruses influences morbillivirus infection outcome. non-invasive pulmonary ferret mri revealed that severe outcomes of consecutive iav/cdv infections were prevented by oral ghp-88309 treatment even when initiated after peak clinical signs of cdv. these findings validate the morbillivirus immune amnesia hypothesis, define treatment paradigms for measles, identify prior disease history as risk factor for exacerbated morbillivirus disease, and demonstrate that treating morbillivirus infection with direct-acting oral antivirals provides therapeutic benefit regardless of whether the time window to mitigate primary clinical signs of infection has closed."}, {"Link/DOI": "https://doi.org/10.1101/2023.05.17.23290110", "Publication Date": "2024-02-07 00:00:00", "Title": "accuracy of digital chest x-ray analysis with artificial intelligence software as a triage and screening tool in hospitalized patients being evaluated for tuberculosis in lima, peru.", "ID Score": "0.9999889", "Team Score": "0.9937144", "Authors": "['Biewer, A. M.; Tzelios, C.; Tintaya, K.; Roman, B.; Hurwitz, S.; Yuen, C.; Mitnick, C. D.; Nardell, E.; Lecca, L.; Tierney, D. B.; Nathavitharana, R. R.']", "Abstract": "introductiontuberculosis (tb) transmission in healthcare facilities is common in high-incidence countries. yet, the optimal approach for identifying inpatients who may have tb is unclear. we evaluated the diagnostic accuracy of qxr (qure.ai, india) computer-aided detection (cad) software versions 3.0 and 4.0 (v3 and v4) as a triage and screening tool within the fast (find cases actively, separate safely, and treat effectively) transmission control strategy.  methodswe prospectively enrolled two cohorts of patients admitted to a tertiary hospital in lima, peru: one group had cough or tb risk factors (triage) and the other did not report cough or tb risk factors (screening). we evaluated the sensitivity and specificity of qxr for the diagnosis of pulmonary tb using culture and xpert as primary and secondary reference standards, including stratified analyses based on risk factors.  resultsin the triage cohort (n=387), qxr v4 sensitivity was 0.91 (59/65, 95% ci 0.81-0.97) and specificity was 0.32 (103/322, 95% ci 0.27-0.37) using culture as reference standard. there was no difference in the area under the receiver-operating-characteristic curve (auc) between qxr v3 and qxr v4 with either a culture or xpert reference standard. in the screening cohort (n=191), only one patient had a positive xpert result, but specificity in this cohort was high (>90%). a high prevalence of radiographic lung abnormalities, most notably opacities (81%), consolidation (62%), or nodules (58%), was detected by qxr on digital cxr images from the triage cohort.  conclusionsqxr had high sensitivity but low specificity as a triage in hospitalized patients with cough or tb risk factors. screening patients without cough or risk factors in this setting had a low diagnostic yield. these findings further support the need for population and setting-specific thresholds for cad programs."}, {"Link/DOI": "https://doi.org/10.1101/2023.08.09.23293885", "Publication Date": "2024-02-07 00:00:00", "Title": "self-tests for covid-19: what is the evidence? a living systematic review and meta-analysis (2020-2023)", "ID Score": "0.9999896", "Team Score": "0.97622174", "Authors": "[\"Anand, A.; Vialard, F.; Esmail, A.; Ahmad Khan, F.; O'Byrne, P.; Routy, J.-P.; Dheda, K.; Pant Pai, N.\"]", "Abstract": "covid-19 self-testing strategy (covidst) can rapidly identify symptomatic and asymptomatic sars-cov-2-infected individuals and their contacts, potentially reducing transmission. in this living systematic review, we evaluated the evidence for real-world covidst performance. two independent reviewers searched six databases (pubmed, embase, web of science, world health organization database, cochrane covid-19 registry, europe pmc) for the period april 1st, 2020, to january 18th, 2023. data on studies evaluating covidst against laboratory-based conventional testing and reported on diagnostic accuracy, feasibility, acceptability, impact, and qualitative outcomes were abstracted. bivariate random effects meta-analyses of covidst accuracy were performed (n=14). subgroup analyses (by sampling site, symptomatic/asymptomatic infection, supervised/unsupervised strategy, with/without digital supports) were conducted. data from 70 included studies, conducted across 25 countries with a median sample size of 817 (range: 28-784,707) were pooled. specificity was high overall, irrespective of subgroups (98.37-99.71%). highest sensitivities were reported for: a) symptomatic individuals (73.91%, 95%ci: 68.41-78.75%; n=9), b) mid-turbinate nasal samples (77.79%, 95%ci: 56.03-90.59%; n=14), c) supervised strategy (86.67%, 95%ci: 59.64-96.62%; n=13), and d) presence of digital interventions (70.15%, 95%ci: 50.18-84.63%; n=14). sensitivity was lower in asymptomatic populations (40.18%, 95% ci: 21.52-62.20%; n=4), due to errors in test conduct and absence of supervision or a digital support. we found no difference in covidst sensitivity between delta and omicron pre-dominant period. digital supports increased confidence in covidst reporting and interpretation (n=16). overall acceptability was 91.0-98.7% (n=2) with lower acceptability reported for daily self-testing (39.5-51.1%). feasibility was 69.0-100.0% (n=5) with lower feasibility (35.9-64.6%) for serial self-testing. covidst decreased closures in school, workplace, and social events (n=4). covidst is an effective rapid screening strategy for home-, workplace- or school-based screening, for symptomatic persons, and for preventing transmission during outbreaks. this data is useful for updating covidst policy. our review demonstrates that covidst has paved the way for the introduction of self-tests, worldwide."}, {"Link/DOI": "https://doi.org/10.1101/2023.01.03.522213", "Publication Date": "2024-02-02 00:00:00", "Title": "a gamma-adapted recombinant subunit vaccine induces broadly neutralizing antibodies against sars-cov-2 variants and protects mice from sars-cov-2 infection.", "ID Score": "0.99998915", "Team Score": "0.94508845", "Authors": "['Coria, L. M.; Rodriguez, J. M.; Demaria, A.; Bruno, L. A.; Rios Medrano, M.; Pueblas Castro, C.; Castro, E. F.; Del Priore, S. A.; Hernando Insua, A. C.; Kaufmann, I. G.; Saposnik, L. M.; Stone, W. B.; Prado, L.; Krum, V.; Zurvarra, F. M.; Sidabra, J. E.; Drehe, I.; Baque, J. A.; Li Causi, M.; De Nichilo, A. V.; Payes, C. J.; Auguste, A. J.; Vega, J. C.; Alvarez, D. E.; Flo, J. M.; Pasquevich, K. A.; Cassataro, J.']", "Abstract": "the covid-19 pandemic continues with the emergence of successive new variants of concern (voc). one strategy to prevent breakthrough infections is developing safe and effective broad-spectrum vaccines. here, we present preclinical studies of a rbd recombinant vaccine candidate derived from the gamma sars-cov-2 variant adjuvanted with alum. gamma rbd-derived antigen elicited better neutralizing antibody and t cell responses than formulation containing ancestral rbd antigen. the gamma-adapted subunit vaccine elicited a long-lasting antibody response with cross-neutralizing activity against different voc including the omicron variant. additionally, gamma variant rbd-adapted vaccine elicited robust t cells responses with induction of th1 and cd8+ t cell responses in spleen and lung. vaccine-induced immunity protected k18-hace2 mice from intranasal challenge with sars-cov-2 increasing survival, reducing body weight loss and viral burden in the lungs and brain. importantly, the subunit vaccine demonstrated a potent effect as heterologous booster of different vaccine platforms including the non-replicating adenovirus vaccine chadox1-s, the mrna vaccine bnt162b2 and the inactivated sars-cov-2 vaccine bbibp-corv, increasing cross-reactive antibody responses. our study indicates that the adjuvanted gamma rbd vaccine is highly immunogenic and a broad-spectrum vaccine candidate to combat sars-cov-2 variants including omicron."}, {"Link/DOI": "https://doi.org/10.1101/2023.01.09.523209", "Publication Date": "2024-02-02 00:00:00", "Title": "identification of druggable host dependency factors shared by multiple sars-cov-2 variants of concern", "ID Score": "0.99998975", "Team Score": "0.9322395", "Authors": "['Frasson, I.; Diamante, L.; Zangrossi, M.; Carbognin, E.; Dalla Pieta, A.; Penna, A.; Rosato, A.; Verin, R.; Torrigiani, F.; Salata, C.; Vaccaro, L.; Cacchiarelli, D.; Richter, S. N.; Montagner, M.; Martello, G.']", "Abstract": "the high mutation rate of sars-cov-2 leads to emergence of several variants, some of which are resistant to vaccines and drugs targeting viral elements. targeting host dependency factors - cell proteins required for viral replication - would help avoid resistance. however, whether different sars-cov-2 variants induce conserved cell responses and exploit the same core host factors is still unclear.  we compared three variants of concern and observed that the host transcriptional response was conserved, differing only in kinetics and magnitude. by crispr screening we identified the host genes required for infection by each variant: most of the identified genes were shared by multiple variants, both in lung and colon cells. we validated our hits with small molecules and repurposed fda-approved drugs. all drugs were highly effective against all tested variants, including delta and omicron, new variants that emerged during the study. mechanistically, we identified ros production as a pivotal step in early virus propagation. antioxidant drugs, such as n-acetyl cysteine (nac), were effective against all variants both in human lung cells, and in a humanised mouse model. our study supports the use of available antioxidant drugs, such as nac, as a general and effective anti-covid-19 approach."}, {"Link/DOI": "https://doi.org/10.1101/2023.07.13.23291675", "Publication Date": "2024-02-02 00:00:00", "Title": "global safety assessment of adverse events of special interest following 2 years of use and 772 million administered doses of mrna-1273", "ID Score": "0.9999893", "Team Score": "0.9819324", "Authors": "['Urdaneta, V.; Esposito, D. B.; Dharia, P.; Stam Moraga, M.; Anteyi, K.; Oduyebo- Omotosho, T.; Rossi, M.; Burton, P.; Vega, J. M.; Dawson, R.; Straus, W.']", "Abstract": "backgroundthe large-scale use of mrna covid-19 vaccines during the pandemic was associated with enhanced safety monitoring to ensure accurate and timely review of safety. we reviewed the mrna-1273 (original strain) safety profile following 2 years of use (>772 million administered doses), primarily focusing upon predefined safety topics (ie, adverse events of special interest [aesi]) proposed in advance of covid-19 vaccine use.  methodscumulative mrna-1273 safety data from spontaneous adverse event (ae) cases reported to the moderna, inc., global safety database (gsdb) between december 18, 2020, and december 17, 2022, were included. reporting rates of aesi were calculated per 1 million doses of mrna-1273 administered. observed-to-expected (oe) ratios were computed by comparing observed rates of aesi to the background/expected rate for these events to evaluate potential associations with mrna-1273.  resultsthere were 658,767 identified case reports, associated with 2,517,669 aes. most aes were non-serious (83.4%); 0.7% were fatal. aesi represented 13.7% of all aes, with reporting rates for most aesi below the expected background incidence. exceptions included anaphylaxis (oe ratio 3 days after vaccination, 2.19 [95% ci, 2.02-2.37]), myocarditis (oe ratio 7 days after vaccination, 1.41 [1.32-1.51]; among men aged 12-40 years, 9.75 [7.74-12.3]; and individuals aged 12-40 years, 3.51 [3.19-3.86]), and pericarditis (oe ratio 7 days after vaccination in individuals aged 12-40 years, 2.54 [2.16-2.99]).  conclusionswith the exceptions of anaphylaxis, myocarditis, and pericarditis, this safety analysis of mrna-1273 did not find evidence to suggest an increased risk for aesi identified for enhanced monitoring ahead of covid-19 vaccine use."}, {"Link/DOI": "https://doi.org/10.1101/2023.08.10.23293680", "Publication Date": "2024-02-02 00:00:00", "Title": "new manual qpcr assay validated on tongue swabs collected and processed in uganda shows sensitivity that rivals sputum-based molecular tb diagnostics", "ID Score": "0.99998903", "Team Score": "0.9522104", "Authors": "['Steadman, A. E.; Andama, A. O. E.; Ball, A.; Mukwatamundu, J.; Khimani, K.; Mochizuki, T.; Asege, L.; Bukirwa, A.; Kato, J. B.; Katumba, D.; Kisakye, E.; Mangeni, W.; Mwebe, S.; Nakawesa, A.; Nakaye, M.; Nassuna, I.; Nyawere, J.; Cook, C.; Nalugwa, T.; Bachman, C. M.; Semitala, F. C.; Weigl, B. H.; Connelly, J. T.; Worodria, W.; Cattamanchi, A.']", "Abstract": "backgroundreliance on sputum-based testing is a key barrier to increasing access to molecular diagnostics for tuberculosis (tb). many people with tb are unable to produce and sputum processing increases the complexity and cost of molecular assays. tongue swabs are emerging as an alternative to sputum, but performance limits are uncertain.  methodsfrom june 2022 to july 2023, we enrolled 397 consecutive adults with cough >2 weeks at two health centers in kampala, uganda. we collected routine demographic and clinical information, sputum for routine tb testing (one xpert mtb/rif ultra(r) and two liquid cultures), and up to four tongue swabs for same-day qpcr. we evaluated tongue swab qpcr diagnostic accuracy in reference to sputum tb test results, quantified tb targets per swab, assessed the impact of serial swabbing, and compared two swab types (copan floqswab(r) and steripack(r) spun polyester swabs).  resultsamong 397 participants, 43.1% were female, median age was 33 years, 23.5% were living with hiv (plhiv) and 32.3% had confirmed tb. sputum xpert ultra and tongue swab qpcr results were concordant for 98.2% [96.2-99.1] of participants. tongue swab qpcr sensitivity was 91.0% [84.6-94.9] and specificity 98.9% [96.2-99.8] vs. microbiological reference standard (mrs). a single tongue swab recovered a seven-log range of tb copies, with a decreasing recovery trend among four serial swabs. we found no difference between swab types.  conclusionstongue swabs show promise as an alternative to sputum for tb diagnosis, with sensitivity approaching sputum-based molecular tests. our results provide valuable insights for developing successful tongue swab-based tb diagnostics."}, {"Link/DOI": "https://doi.org/10.1101/2023.06.29.23292043", "Publication Date": "2024-02-02 00:00:00", "Title": "risk of sars-cov-2 reinfection during multiple omicron variant waves in the uk general population", "ID Score": "0.99998987", "Team Score": "0.87500614", "Authors": "['Wei, J.; Stoesser, N.; Matthews, P.; Khera, T.; Gethings, O.; Diamond, I.; Studley, R.; Taylor, N.; peto, t. E.; Walker, A. S.; Pouwels, K.; Eyre, D. W.']", "Abstract": "sars-cov-2 reinfections increased substantially after omicron variants emerged. large-scale community-based comparisons across multiple omicron waves of reinfection characteristics, risk factors, and protection afforded by previous infection and vaccination, are limited, especially after widespread national testing stopped. we studied 245,895 adults [&ge;]18y in the uks national covid-19 infection survey with at least one infection (identified from positive swab tests done within the study, linked from national testing programmes, or self-reported by participants, up to their last study assessment). we quantified the risk of reinfection in multiple infection waves, including those driven by ba.1, ba.2, ba.4/5, and most recently bq.1/ch.1.1/xbb.1.5 variants, in which most reinfections occurred. reinfections had higher cycle threshold (ct) values (lower viral load) and lower percentages self-reporting symptoms compared with first infections. across multiple omicron waves, protection against reinfection was significantly higher in those previously infected with more recent than earlier variants, even at the same time from previous infection. protection against omicron reinfections decreased over time from the most recent infection if this was the previous or penultimate variant (generally within the preceding year), but did not change or even slightly increased over time if this was with an even earlier variant (generally >1 year previously). those 14-180 days after receiving their most recent vaccination had a lower risk of reinfection with all omicron variants except ba.2 than those >180 days from their most recent vaccination. reinfection risk was independently higher in those aged 30-45 years, and with either low or high ct values in their most recent previous infection. overall, the risk of omicron reinfection is high, but with lower severity than first infections; reinfection risk is likely driven as much by viral evolution as waning immunity."}, {"Link/DOI": "https://doi.org/10.1101/2023.08.01.551509", "Publication Date": "2024-02-01 00:00:00", "Title": "strong immunogenicity & protection in mice with placcine: a covid-19 dna vaccine formulated with a functional polymer", "ID Score": "0.9999896", "Team Score": "0.9161083", "Authors": "['Sood, S.; Matar, M.; Kim, J.; Kinsella, M.; Rayavara, K.; Signer, O.; Henderson, J.; Smith, A.; Rogers, J.; Chawla, B.; Van Ry, A.; Narvaez, B.; Kar, S.; Arnold, A.; Su, D.; Rice, J.; Sparks, J.; Le Goff, C.; Boyer, J. D.; Anwer, K.']", "Abstract": "dna- based vaccines have demonstrated the potential as a safe and effective modality. placcine, a dna-based vaccine approach described subsequently relies on a synthetic dna delivery system and is independent of virus or device. the synthetic functionalized polymer combined with dna demonstrated stability over 12 months at 4c and for one month at 25c. transfection efficiency compared to naked dna increased by 5-15-fold in murine skeletal muscle. studies of dna vaccines expressing spike proteins from variants d614g (pvac15), delta (pvac16), or a d614g + delta combination (pvac17) were conducted. mice immunized intramuscular injection (im) with pvac15, pvac16 or pvac17 formulated with functionalized polymer and adjuvant resulted in induction of spike-specific humoral and cellular responses. antibody responses were observed after one immunization. and endpoint igg titers increased to greater than 1x 105 two weeks after the second injection. neutralizing antibodies as determined by a pseudovirus competition assay were observed following vaccination with pvac15, pvac16 or pvac17. spike specific t cell immune responses were also observed following vaccination and flow cytometry analysis demonstrated the cellular immune responses included both cd4 and cd8 spike specific t cells. the immune responses in vaccinated mice were maintained for up to 14 months after vaccination. in an immunization and challenge study of k18 hace2 transgenic mice pvac15, pvac16 and pvac17 induced immune responses lead to decreased lung viral loads by greater than 90% along with improved clinical score. these findings suggest that placcine dna vaccines are effective and stable and further development against emerging sars-cov-2 variants is warranted."}, {"Link/DOI": "https://doi.org/10.1101/2022.09.23.22280285", "Publication Date": "2024-01-31 00:00:00", "Title": "dimethyl fumarate in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial", "ID Score": "0.99998915", "Team Score": "0.9940328", "Authors": "['RECOVERY Collaborative Group,  ; Horby, P. W.; Peto, L.; Staplin, N.; Campbell, M.; Pessoa-Amorim, G.; Mafham, M.; Emberson, J. R.; Stewart, R.; Prudon, B.; Uriel, A.; Green, C. A.; Dhasmana, D. J.; Malein, F.; Majumdar, J.; Collini, P.; Shurmer, J.; Yates, B.; Baillie, J. K.; Buch, M. H.; Day, J. N.; Faust, S. N.; Jaki, T.; Jeffery, K.; Juszczak, E.; Knight, M.; Lim, W. S.; Montgomery, A.; Mumford, A.; Rowan, K.; Thwaites, G.; Haynes, R.; Landray, M.']", "Abstract": "backgrounddimethyl fumarate (dmf) is an anti-inflammatory drug that has been proposed as a treatment for patients hospitalised with covid-19  methodsthis randomised, controlled, open-label platform trial (randomised evaluation of covid-19 therapy [recovery]), is assessing multiple possible treatments in patients hospitalised for covid-19. in this initial assessment of dmf, performed at 27 uk hospitals, eligible and consenting adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus dmf 120mg twice daily for 2 days followed by 240mg twice daily for 8 days, or until discharge if sooner. the primary outcome was clinical status on day 5 measured on a seven-point ordinal scale, assessed using a proportional odds model. secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 c-reactive protein, and improvement in day 10 clinical status. the trial is registered with isrctn (50189673) and clinicaltrials.gov (nct04381936).  findingsbetween 2 march 2021 and 18 november 2021, 713 patients were enrolled in the dmf evaluation, of whom 356 were randomly allocated to receive usual care plus dmf, and 357 to usual care alone. 95% of patients were receiving corticosteroids as part of routine care. there was no evidence of a beneficial effect of dmf on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% ci 0.85-1.46; p=0.42). there was no significant effect of dmf on any secondary outcome. as expected, dmf caused flushing and gastrointestinal symptoms, each in around 6% of patients, but no new adverse effects were identified.  interpretationin adults hospitalised with covid-19, dmf was not associated with an improvement in clinical outcomes.  fundinguk research and innovation (medical research council) and national institute of health research (grant ref: mc_pc_19056)."}, {"Link/DOI": "https://doi.org/10.1101/2021.04.06.21254612", "Publication Date": "2024-01-31 00:00:00", "Title": "making sense of non-randomized comparative treatment studies in times of covid-19: a case study of tocilizumab", "ID Score": "0.9999896", "Team Score": "0.9949767", "Authors": "['Owen, R. R. C.; Qizilbash, N.; Diaz, S. V.; Vazquez, J. M. C.; Pocock, S. J.']", "Abstract": "backgroundtocilizumab (tcz) is an interleukin-6 inhibitor and the second established effective drug for the treatment of hospitalized patients with covid-19. in this study, we sought to validate the recent positive findings from the randomised clinical trial recovery and to evaluate the challenges in the analysis and interpretation of non-randomized comparative effectiveness studies in covid-19.  methodswe performed a retrospective cohort study using an openly available database of hospitalised covid-19 patients in spain. the primary outcome was all-cause in-hospital mortality at 28 days. we used multivariable fine and gray competing risk models which adjusted for both fixed and time-variant confounders to investigate the effect of tcz on the primary outcome.  resultswe analysed 2547 patients hospitalised with covid-19 between 1st january and 28th june 2020. patients in the tcz group tended to have more severe covid-19 at admission, as measured by biomarkers of disease severity including crp, d-dimer and ldh. at 28 days, 91 out of 440 tcz patients had died compared to 267 out of 2107 patients in the control group. in multivariable analysis, there was no evidence of an association between tcz and the primary outcome (adjusted hazard ratio 1.20, 95% ci 0.86 to 1.64, p=0.26).  conclusionsour observational study failed to find a benefit of tcz on all-cause in-hospital mortality in covid-19 patients compared with randomized trials, highlighting the impact that unmeasured confounding and other sources of bias can have in a retrospective observational setting. for future observational studies, we recommend prospective data collection to ensure all variables have the necessary quality, completeness and timing for reliable treatment evaluation."}, {"Link/DOI": "https://doi.org/10.1101/2023.05.15.23290012", "Publication Date": "2024-01-29 00:00:00", "Title": "the spectrum of psychiatric manifestations in subacute sclerosing panencephalitis: a systematic review of published case reports and case series", "ID Score": "0.9999896", "Team Score": "0.9783609", "Authors": "['Garg, R. K.; Kar, S. K.; Malhotra, H. S.; Pandey, S.; Jain, A.; Rizvi, I.; Uniyal, R.; Kumar, N.']", "Abstract": "backgrounddata related to psychiatric manifestations in sspe is currently available only in form of isolated case reports. in this systematic review, we evaluated the spectrum of psychiatric manifestations and their impact on the course and outcome of sspe.  methodsdata were obtained from four databases (pubmed, embase, scopus, and google scholar), with the most recent search conducted on 27/03/2023. the prisma guidelines were followed, and the prospero registration number for the protocol is crd42023408227. sspe was diagnosed using dykens criteria. extracted data were recorded in an excel spreadsheet. to evaluate the quality of the data, the joanna briggs institute critical appraisal tool was employed.  resultsour search resulted in 30 published reports of 32 patients. the mean age was 17.9 years. schizophrenia, catatonia, and poorly characterized psychotic illnesses were the three most common psychiatric presentations (60%) in sspe cases. mania or depression was reported among 23% (7/32) cases. in 10% of cases, the initial clinical presentation of sspe was considered functional/ hysterical. in approximately 81% (26/32) cases, the course of sspe was rapidly progressive (either acute fulminant or subacute). treatment with antipsychotic drugs had poor or no response. out of 17 patients who received antipsychotic drugs 6 patients noted severe extrapyramidal adverse effects, that further deteriorated the clinical condition of the patients.  conclusionseveral patients with sspe inadvertently end up in psychiatric care due to some psychiatric manifestation. early psychiatric disorders in sspe are often subtle and diagnosis of sspe is easily missed."}, {"Link/DOI": "https://doi.org/10.1101/2023.09.12.23295445", "Publication Date": "2024-01-25 00:00:00", "Title": "determinants of sars-cov-2 igg response and decay in canadian healthcare workers: a prospective cohort study.", "ID Score": "0.9999896", "Team Score": "0.9735996", "Authors": "['Cherry, N.; Adisesh, A.; Burstyn, I.; Charlton, C.; Chen, Y.; Durand-Moreau, Q.; Labreche, F.; Ruzycki, S.; Turnbull, L.; Zadunayski, T.; Yasui, Y.']", "Abstract": "introductionhealthcare workers (hcws) from an interprovincial canadian cohort were asked to give serial blood samples to identify factors associated with anti-receptor binding domain (anti-rbd) igg response to the sars-cov-2 virus.  methodsmembers of the hcw cohort donated blood samples four months after their first sars-cov-2 immunization and again at 7, 10 and 13 months. date and type of immunizations and dates of sars-cov-2 infection were collected at each of four contacts, together with information on immunologically-compromising conditions and current therapies. blood samples were analyzed centrally for anti-rbd igg and anti-nucleocapsid igg (abbott architect, abbott diagnostics). records of immunization and sars-cov-2 testing from public health agencies were used to assess the impact of reporting errors on estimates from the random-effects multivariable model fitted to the data.  results2752 of 4567 vaccinated cohort participants agreed to donate at least one blood sample. modelling of anti-rbd igg titer from 8903 samples showed an increase in igg with each vaccine dose and with first infection. a decrease in igg titer was found with the number of months since vaccination or infection, with the sharpest decline after the third dose. an immunization regime that included mrna1273 (moderna) resulted in higher anti-rbd igg. participants reporting multiple sclerosis, rheumatoid arthritis or taking selective immunosuppressants, tumor necrosis factor inhibitors, calcineurin inhibitors and antineoplastic agents had lower anti-rbd igg. supplementary analyses showed higher anti-rbd igg in those reporting side-effects of vaccination, no relation of anti-rbd igg to obesity and lower titers in women immunized early in pregnancy. sensitivity analysis results suggested no important bias in the self-report data.  conclusioncreation of a prospective cohort was central to the credibility of results presented here. serial serology assessments, with longitudinal analysis, provided effect estimates with enhanced accuracy and a clearer understanding of medical and other factors affecting response to vaccination."}, {"Link/DOI": "https://doi.org/10.1101/2022.07.07.498981", "Publication Date": "2024-01-23 00:00:00", "Title": "biological evaluation of novel side chain containing cqtrich-analogs as antimalarials and their development as pfcdpk1 kinase inhibitors", "ID Score": "0.99998426", "Team Score": "0.8908439", "Authors": "['Irfan, I.; Uddin, A.; Jain, R.; Gupta, A.; Gupta, S.; Napoleon, J. V.; Hussain, A.; Alajmi, M. F.; Joshi, M. C.; Hasan, P.; Abid, M.; Singh, S.']", "Abstract": "to combat the emergence of drug resistance against the existing antimalarials, novel side chain containing 7-chloroquinoline-indole-chalcones tethered with a triazole (cqtrich-analogs 7 (a-s) and 9) were designed and synthesized by reacting substituted 1-phenyl-3-(1-(prop-2-yn-1- yl)-1h-indol-3-yl) prop-2-en-1-one and 1-(prop-2-yn-1-yl)-1h-indole-3-carbaldehyde with 4- azido-7-chloroquinoline, respectively via a  click reaction. the selected cqtrich-analogs: 7l and 7r inhibited chloroquine-sensitive (3d7) and resistant (rkl-9) strains of plasmodium falciparum, with ic50 values of 2.4 {micro}m & 1.8 {micro}m (7l), and 3.5 {micro}m & 2.7 {micro}m (7r), respectively, and showed insignificant hemolysis and cytotoxicity in mammalian cells. intra-erythrocytic progression studies revealed that the active hybrids: 7l and 7r are effective against the mature stages of the parasite. given the importance of calcium-dependent protein kinase 1 (pfcdpk1) in the parasite biology, notably during late schizogony and subsequent invasion of merozoites into host rbcs, we identified this protein as a possible molecular target of these active hybrids. in silico interaction analysis indicated that 7l and 7r stably interact with the catalytically active atp-binding pocket of pfcdpk1, by the formation of energetically favorable h-bonds. furthermore, in vitro microscale thermophoresis and kinase assays with recombinant pfcdpk1 demonstrated that the active hybrids interact with and inhibit the kinase activity, thus presumably responsible for the parasite growth inhibition. interestingly, 7l and 7r showed no inhibitory effect on the human kinases, indicating that they are selective for the parasite kinase. conceivably, we report the antiplasmodial potential of novel kinase targeting bio-conjugates, a step towards developing pan-kinase inhibitors, which is a prerequisite for cross-stage anti-malarial protection.  graphical abstract  o_fig o_linksmallfig width=200 height=115 src=\"figdir/small/498981v1_ufig1.gif\" alt=\"figure 1\"> view larger version (22k): org.highwire.dtl.dtlvardef@113574borg.highwire.dtl.dtlvardef@c81a33org.highwire.dtl.dtlvardef@1301d22org.highwire.dtl.dtlvardef@1c8cac5_hps_format_figexp  m_fig c_fig"}, {"Link/DOI": "https://doi.org/10.1101/2023.10.18.563016", "Publication Date": "2024-01-23 00:00:00", "Title": "th2 and th17-associated immunopathology following sars-cov-2 breakthrough infection in spike-vaccinated ace2-humanized mice", "ID Score": "0.99998915", "Team Score": "0.819629", "Authors": "['Zhang, T.; Magazine, N.; McGee, M. C.; Carossino, M.; Veggiani, G.; Kousoulas, K. G.; August, A.; Huang, W.']", "Abstract": "vaccines have demonstrated remarkable effectiveness in protecting against covid-19; however, concerns regarding vaccine-associated enhanced respiratory diseases (vaerd) following breakthrough infections have emerged. spike protein subunit vaccines for sars-cov-2 induce vaerd in hamsters, where aluminum adjuvants promote a th2-biased immune response, leading to increased type 2 pulmonary inflammation in animals with breakthrough infections. to gain a deeper understanding of the potential risks and the underlying mechanisms of vaerd, we immunized ace2-humanized mice with sars-cov-2 spike protein adjuvanted with aluminum and cpg-odn. subsequently, we exposed them to increasing doses of sars-cov-2 to establish a breakthrough infection. the vaccine elicited robust neutralizing antibody responses, reduced viral titers, and enhanced host survival. however, following a breakthrough infection, vaccinated animals exhibited severe pulmonary immunopathology, characterized by a significant perivascular infiltration of eosinophils and cd4+ t cells, along with increased expression of th2/th17 cytokines. intracellular flow cytometric analysis revealed a systemic th17 inflammatory response, particularly pronounced in the lungs. our data demonstrate that aluminum/cpg adjuvants induce strong antibody and th1-associated immunity against covid-19 but also prime a robust th2/th17 inflammatory response, which may contribute to the rapid onset of t cell-mediated pulmonary immunopathology following a breakthrough infection. these findings underscore the necessity for further research to unravel the complexities of vaerd in covid-19 and to enhance vaccine formulations for broad protection and maximum safety.  significance statementthis research investigates the safety and efficacy of a spike protein subunit vaccine adjuvanted with alum and cpg in an ace2-humanized mouse model, simulating sars-cov-2 breakthrough infections. the study reveals that despite robust protection against severe covid-19, vaccinated mice exhibit substantial pulmonary immunopathology, including eosinophilia and enhanced th2 effector immunity, following breakthrough infections. surprisingly, the study also uncovers a significant systemic th17 inflammatory response in vaccinated mice. this research sheds light on the potential risks associated with covid-19 vaccine breakthrough infections and the need for a comprehensive understanding of vaccine-induced immune responses, emphasizing the importance of ongoing research, surveillance, and careful vaccine development for both protection and safety in the fight against the covid-19 pandemic."}, {"Link/DOI": "https://doi.org/10.1101/2022.03.22.22272770", "Publication Date": "2024-01-23 00:00:00", "Title": "long-term symptoms after sars-cov-2 infection in a cohort of hospital employees: duration and predictive factors", "ID Score": "0.9999894", "Team Score": "0.9141559", "Authors": "['Gruber, R.; Montilva Ludewig, M. V.; Wessels, C.; Schlang, G.; Jedhoff, S.; Herbrandt, S.; Mattner, F.']", "Abstract": "objectiveto evaluate the frequency, duration and patterns of long-term coronavirus disease 2019 (covid-19) symptoms and to analyze risk factors for long-lasting covid-19 sequelae among hospital employees (hes).  designretrospective observational cohort study.  settingthree medical centers in cologne, germany.  participantswe included hes who had a positive severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polymerase chain reaction (pcr) test between march 2020 and may 2021.  methodswe conducted a survey in mid-2021 with all hes tested sars-cov-2 pcr positive during the study period and asked about the presence and duration of 24 different covid-19 related symptoms. chronological development and patterns of symptom complexes, probability of symptom persistence and possible risk factors for protracted covid-19 course were analyzed.  resultsof 221 included hes, a number of 104 hes (47.1%) reported at least one persisting symptom for more than 90 days after initial sars-cov-2 detection. a symptom duration over 28 days was associated with multiple symptom complexes. the most common was the interrelated occurrence of shortness of breath, memory disorder, concentration disorders and fatigue. each one cycle higher initial ct value significantly increased the chances of overcoming symptoms (odds ratio [or] = 1.05; p = 0.019). the occurrence of breathlessness within the first ten days (or = 7.89; p = 0.008), an initial ct value under 30 (or = 3.36; p = 0.022) and a definitely nosocomial sars-cov-2 transmission (or = 3.05; p = 0.049) showed a statistically significant association with increased odds of illness duration over 90 days.  conclusionabout half of the hes suffered from long lasting symptoms over 90 days after almost entirely mild acute covid-19. different symptom complexes could be shown and predictive factors for long-term symptoms were identified. predictive factors at the onset of the infection could possibly be used for early treatment to prevent development of long-term symptoms after covid-19 in future."}, {"Link/DOI": "https://doi.org/10.1101/2023.05.24.541850", "Publication Date": "2024-01-22 00:00:00", "Title": "cross-protection induced by highly conserved human b, cd4+, and cd8+ t cell epitopes-based coronavirus vaccine against severe infection, disease, and death caused by multiple sars-cov-2 variants of concern", "ID Score": "0.9999894", "Team Score": "0.90765446", "Authors": "['Prakash, S. F.; Dhanushkodi, N. R.; Zayou, L.; Ibraim, I. C.; Quadiri, A.; Coulon, P. G.; Tifrea, D. F.; Suzler, B.; Amin, M.; Chilukuri, A.; Edwards, R. A.; Vahed, H.; Nesburn, A. B.; Kuppermann, B. D.; Ulmer, J. B.; Gil, D.; Jones, T. M.; BenMohamed, L.']", "Abstract": "backgroundthe coronavirus disease 2019 (covid-19) pandemic has created one of the largest global health crises in almost a century. although the current rate of sars-cov-2 infections has decreased significantly; the long-term outlook of covid-19 remains a serious cause of high death worldwide; with the mortality rate still surpassing even the worst mortality rates recorded for the influenza viruses. the continuous emergence of sars-cov-2 variants of concern (vocs), including multiple heavily mutated omicron sub-variants, have prolonged the covid-19 pandemic and outlines the urgent need for a next-generation vaccine that will protect from multiple sars-cov-2 vocs.  methodsin the present study, we designed a multi-epitope-based coronavirus vaccine that incorporated b, cd4+, and cd8+ t cell epitopes conserved among all known sars-cov-2 vocs and selectively recognized by cd8+ and cd4+ t-cells from asymptomatic covid-19 patients irrespective of voc infection. the safety, immunogenicity, and cross-protective immunity of this pan-coronavirus vaccine were studied against six vocs using an innovative triple transgenic h-ace-2-hla-a2/dr mouse model.  resultsthe pan-coronavirus vaccine: (i) is safe; (ii) induces high frequencies of lung-resident functional cd8+ and cd4+ tem and trm cells; and (iii) provides robust protection against virus replication and covid-19-related lung pathology and death caused by six sars-cov-2 vocs: alpha (b.1.1.7), beta (b.1.351), gamma or p1 (b.1.1.28.1), delta (lineage b.1.617.2) and omicron (b.1.1.529). conclusions: a multi-epitope pan-coronavirus vaccine bearing conserved human b and t cell epitopes from structural and non-structural sars-cov-2 antigens induced cross-protective immunity that cleared the virus, and reduced covid-19-related lung pathology and death caused by multiple sars-cov-2 vocs."}, {"Link/DOI": "https://doi.org/10.1101/2023.08.25.554813", "Publication Date": "2024-01-22 00:00:00", "Title": "in vivo antiviral efficacy of lctg-002, a pooled, purified human milk secretory iga product, against sars-cov-2 in a murine model of covid-19", "ID Score": "0.9999894", "Team Score": "0.989242", "Authors": "['Mane, V.; Mehta, R.; Alvarez, N.; Sharma, V.; Park, S.; Fox, A.; DeCarlo, C.; Yang, X.; Perlin, D. S.; Powell, R. L.']", "Abstract": "immunoglobulin a (iga) is the most abundant antibody (ab) in human mucosal compartments including the respiratory tract, with the secretory form of iga (siga) being dominant and uniquely stable in these environments. siga is naturally found in human milk, which could be considered a global resource for this biologic, justifying the development of human milk siga as a dedicated airway therapeutic for respiratory infections such as sars-cov-2. in the present study, methods were therefore developed to efficiently extract human milk siga from donors who were either immunologically naive to sars-cov-2 (pooled as a control iga) or had recovered from a pcr-confirmed sars-cov-2 infection that elicited high-titer anti-sars-cov-2 spike siga abs in their milk (pooled together to make lctg-002). mass spectrometry determined that proteins with a relative abundance of 1.0% or greater were all associated with siga. none of the proteins exhibited statistically significant differences between batches. western blot demonstrated all batches consisted predominantly of siga. compared to control iga, lctg-002 demonstrated significantly higher binding to spike, and was also capable of blocking the spike - ace2 interaction in vitro with 6.3x greater potency compared to control iga (58% inhibition at [~]240ug/ml). lctg-002 was then tested in vivo for its capacity to reduce viral burden in the lungs of k18+hace2 transgenic mice inoculated with sars-cov-2. lctg-002 was demonstrated to significantly reduce sars-cov-2 titers in the lungs compared to control iga when administered at either 250ug/day or 1 mg/day, as measured by tcid50, plaque forming units (pfu), and qrt-pcr, with a maximum reduction of 4.9 logs. this innovative study demonstrates that lctg-002 is highly pure, efficacious, and well tolerated in vivo, supporting further development of milk-derived, polyclonal siga therapeutics against sars-cov-2 and other mucosal infections."}, {"Link/DOI": "https://doi.org/10.1101/2023.08.28.23294721", "Publication Date": "2024-01-22 00:00:00", "Title": "prediction models for adverse drug reactions during tuberculosis treatment in brazil", "ID Score": "0.9999893", "Team Score": "0.9087462", "Authors": "['Ridolfi, F.; Amorim, G.; Peetluk, L.; Haas, D.; Staats, C.; Araujo-Pereira, M.; Cordeiro-Santos, M.; Kritski, A. L.; Figueiredo, M. C.; Andrade, B. B.; Rolla, V. C.; Sterling, T. R.']", "Abstract": "backgroundtuberculosis (tb) treatment-related adverse drug reactions (tb-adr) can negatively affect adherence and treatment success rates.  methodswe developed two prediction models for tb-adr. we included drug-susceptible pulmonary tb participants who initiated standard tb therapy. tb-adr were determined by physician-assigned attributions of causality, and described according to affected organ system, timing, and grade. potential predictors of tb-adr included concomitant medication (cm) use, hiv-status, glycated hemoglobin (hba1c), age, body mass index (bmi), sex, substance use, and tb drug metabolism variables (e.g., nat2 acetylator profile). bootstrapped backwards selection was used to develop the models. cox proportional hazards regression was used to evaluate tb-adr risk.  resultsthere were 156 tb-adr among 102 (11%) of the 945 participants included. most tb-adr were hepatic (n=82;53%), grade 2 (n=121;78%), and occurred in nat2 slow acetylators (n=62;61%). the main prediction model included cm use, hba1c, alcohol-use, hiv-infection, bmi, and age. the alternative model included the same variables, except replaced bmi with nat2. both models had good performance and fit. cm use and hiv-infection increased tb-adr risk.  conclusionsthe model with only clinical variables and that with nat2 were highly predictive of tb-adr. the nat2 model provides rationale to evaluate isoniazid dose adjustment and adr risk."}, {"Link/DOI": "https://doi.org/10.1101/2023.08.07.23293369", "Publication Date": "2024-01-21 00:00:00", "Title": "effectiveness of one dose of killed oral cholera vaccine in an endemic community in the democratic republic of congo: a matched case-control study", "ID Score": "0.9999889", "Team Score": "0.9276612", "Authors": "['Malembaka, E. B.; Bugeme, P. M.; Hutchins, C.; Xu, H.; Dent, J. D.; Demby, M. N.; Gallandat, K.; Saidi, J. M.; Rumedeka, B. B.; Itongwa, M.; Tshiwedi-Tsilabia, E.; Kitoga, F.; Bodisa-Matamu, T.; Kavunga-Membo, H.; Kulondwa, J.-C.; Bengehya, J.; Debes, A. K.; Taty, N.; Lee, E. C.; Lessler, J.; Leung, D. T.; Cumming, O.; Okitayemba, P. W.; Mukadi-Bamuleka, D.; Knee, J.; Azman, A. S.']", "Abstract": "backgrounda global shortage of cholera vaccines has increased the use of single-dose regimens, rather than the standard two-dose regimen. there is limited evidence on single-dose protection, particularly in children. in 2020, a mass vaccination campaign resulting in largely single dose coverage, was conducted in uvira, an endemic urban setting in eastern democratic republic of the congo. we examined the effectiveness of a single-dose of the oral cholera vaccine euvichol-plus(r) in this high-burden setting.  methodswe recruited medically attended confirmed cholera cases and age-, sex-, and neighborhood-matched community controls during two distinct periods after mass vaccination, october 2021 to march 2022 (12-17 months post-vaccination) and october 2022 to october 2023 (24-36 months post-vaccination). the odds of vaccination in cases and controls were contrasted in conditional logistic regression models to estimate unadjusted and adjusted vaccine effectiveness.  findingswe enrolled 658 confirmed cases and 2,274 matched controls during the two study periods with 15{middle dot}0% of cases being under five years old at the time of vaccination. the adjusted single-dose ve was 52{middle dot}7% (95% ci: 31{middle dot}4-67{middle dot}4) 12-17 months post-vaccination and 45{middle dot}5% (95% ci: 25{middle dot}8- 60{middle dot}0) 24-36 months post-vaccination. while protection in the first 12-17 months post-vaccination was similar for 1-4-year-olds and older individuals, over the third year post-vaccination the estimate of protection in 1-4 year-olds (adjusted ve 33{middle dot}1%; 95% ci: -30{middle dot}0-65{middle dot}6) appeared to wane with confidence intervals spanning the null.  interpretationa single-dose of euvichol-plus(r) provided substantial protection against medically attended cholera for at least 36 months post-vaccination in this cholera endemic setting. while our evidence provides support for comparable levels of protection in young children and others in the short-term, protection among young children may wane significantly by the third year after vaccination.  fundingwellcome trust and gavi (gavi-rfp-2019-062).  research in contexto_st_absevidence before this studyc_st_absin late 2022, due to increasing demand for killed, whole-cell, oral cholera vaccines (kocv) and limited production capacity, the international coordinating group (the organization managing emergency stocks of kocvs) changed policy to deploy single-dose, rather than the standard two-dose regimen, for emergency vaccination campaigns. this decision was in line with who guidance on the use of a single dose in outbreaks, where short-term protection is key. however, this recommendation is based on a limited number of clinical studies with short-term follow-up. there is also limited evidence on the magnitude and duration of protection conferred by a single dose of kocv, particularly in children under five years of age.  we searched pubmed for randomized trials and observational studies published in english before november 1, 2023, that reported estimates of protection conferred by a single dose of kocv, using the term \"(effectiveness or efficacy) and cholera* and vaccine\". we found no published studies estimating the effectiveness of a single dose of euvichol-plus(r), and only one study reporting two-dose effectiveness. despite this paucity of evidence, this is the only vaccine currently available in the global stockpile. to date, there has been one randomized trial conducted in bangladesh between 2014 and 2016, and seven observational studies conducted between 2009 and 2016 in guinea, haiti, india, malawi, sudan, zambia and zanzibar, reporting effectiveness estimates of a single dose of the current generation of kocv. aside from the trial in bangladesh, all estimates were based on secondary analyses that the studies were not powered to estimate. the bangladesh trial is the only study to date that provides an age-stratified estimate of single-dose protection, and while it found an overall protective efficacy of 62% (95% ci: 43- 75) during the 2-year follow up for individuals aged five years or older, it found no significant protection conferred by the shanchol kocv (a bioequivalent of euvichol-plus(r)) for individuals under five years of age (protective efficacy: -44%, 95% ci -220 to 35). four of the seven observational studies provide single-dose vaccine effectiveness (ve) estimates only during the first 12 months post-vaccination with estimates ranging from 43% (95% ci -84-82) in guinea to 93% (95% ci 69-98) in haiti. the three other observational studies providing a single dose ve estimate between 12-30 months post-vaccination were unable to demonstrate statistically significant protection conferred by kocv, with estimates ranging between 32{middle dot}5% (95% ci - 318{middle dot}0-89{middle dot}1) in india and 40% (95% ci -31-73) in haiti. no vaccine protection estimates have been published from the two identified cholera endemic foci in africa, the democratic republic of the congo and nigeria.  added value of this studyin this vaccine effectiveness study, we show that a single dose of euvichol-plus(r) vaccine can provide significant protection against medically attended cholera for up to 36 months after vaccination in a cholera endemic setting in africa, though protection in children under five years old remains unclear. these estimates help fill critical gaps in our understanding of the magnitude and duration of protection from a single dose of the most widely used kocv, euvichol-plus(r) and is one of only a few studies to measure protection in an endemic setting in africa.  implications of all the available evidencethe corpus of available evidence suggests that use of a single dose of kocv in emergency situations where cholera is endemic, like uvira, is justified and that providing a second dose within the first 12-24 months post-vaccination may only provide marginal benefit to the general population. however, more evidence and analyses are needed to weigh the costs and benefits of tailored vaccination approaches for those under five years old, including possibility of providing a second dose at an earlier timepoint."}, {"Link/DOI": "https://doi.org/10.1101/2023.06.30.547169", "Publication Date": "2024-01-17 00:00:00", "Title": "post-exposure intranasal ifn\u03b1 suppresses replication and neuroinvasion of venezualen equine encephalitis virus within olfactory sensory neurons", "ID Score": "0.9999893", "Team Score": "0.84936094", "Authors": "['Klein, R. S.; Cain, M. D.; Klein, N. R.; Jiang, X.']", "Abstract": "venezuelan equine encephalitis virus (veev) may enter the central nervous system (cns) within olfactory sensory neurons (osn) that originate in the nasal cavity after intranasal exposure. while it is known that veev has evolved several mechanisms to inhibit type i interferon (ifn) signaling within infected cells, whether this inhibits virologic control during neuroinvasion along osn has not been studied. here, we utilized an established murine model of intranasal infection with veev to assess the cellular targets and ifn signaling responses after veev exposure. we found that immature osn, which express higher levels of the veev receptor ldlrad3 than mature osn, are the first cells infected by veev. despite rapid veev neuroinvasion after intranasal exposure, olfactory neuroepithelium (one) and olfactory bulb (ob) ifn responses, as assessed by evaluation of expression of interferon signaling genes (isg), are delayed for up to 48 hours during veev neuroinvasion, representing a potential therapeutic window. indeed, a single intranasal dose of recombinant ifn triggers early isg expression in both the nasal cavity and ob. when administered at the time of or early after infection, ifn treatment delayed onset of sequelae associated with encephalitis and extended survival by several days. veev replication after ifn treatment was also transiently suppressed in the one, which inhibited subsequent invasion into the cns. our results demonstrate a critical and promising first evaluation of intranasal ifn for the treatment of human encephalitic alphavirus exposures.  author summaryvenezuelan equine encephalitis virus (veev) may enter the brain through the nasal cavity upon intranasal exposure. the nasal cavity normally displays brisk antiviral immune responses, thus it is unclear why this type of exposure leads to fatal veev infection. using an established murine model of intranasal infection with veev we identified the initial targets of infection within the nasal cavity and found that antiviral immune responses to virus at this site and during brain infection are delayed for up to 48 hours. thus, administration of a single intranasal dose of recombinant ifn at the time of or early after infection improved early antiviral immune responses and suppressed viral replication, which delayed onset of brain infection and extended survival by several days. veev replication after ifn treatment was also transiently suppressed in the nasal cavity, which inhibited subsequent invasion into the cns. our results demonstrate a critical and promising first evaluation of intranasal ifn for the treatment of human veev exposures."}, {"Link/DOI": "https://doi.org/10.1101/2023.08.09.552590", "Publication Date": "2024-01-17 00:00:00", "Title": "characterization of a selective, iron-chelating antifungal compound that disrupts fungal metabolism and synergizes with fluconazole", "ID Score": "0.99545693", "Team Score": "0.97691214", "Authors": "['Corrales, J.; Ramos-Alonso, L.; Gonzalez-Sabin, J.; Rios-Lombardia, N.; Trevijano-Contador, N.; Engen Berg, H.; Sved Skottvoll, F.; Moris, F.; Zaragoza, O.; Chymkowitch, P.; Garcia, I.; Enserink, J.']", "Abstract": "fungal infections are a growing global health concern due to the limited number of available antifungal therapies as well as the emergence of fungi that are resistant to first-line antimicrobials, particularly azoles and echinocandins. development of novel, selective antifungal therapies is challenging due to similarities between fungal and mammalian cells. an attractive source of potential antifungal treatments is provided by ecological niches co-inhabited by bacteria, fungi and multicellular organisms, where complex relationships between multiple organisms has resulted in evolvement of a wide variety of selective antimicrobials. here, we characterized several analogs of the one such natural compound, collismycin a. we show that nr-6226c has antifungal activity against several pathogenic candida species, including c. albicans and c. glabrata, whereas it only has little toxicity against mammalian cells. mechanistically, nr-6226c selectively chelates iron, which is a limiting factor for pathogenic fungi during infection. as a result, nr-6226c treatment causes severe mitochondrial dysfunction, leading to formation of reactive oxygen species, metabolic reprogramming and a severe reduction in atp levels. using an in vivo model for fungal infections, we show that nr-6226c significantly increases survival of candida-infected galleria mellonella larvae. finally, our data indicate that nr-6226c synergizes strongly with fluconazole in inhibition of c. albicans. taken together, nr-6226c is a promising antifungal compound that acts by chelating iron and disrupting mitochondrial functions.  importance statementdrug-resistant fungal infections are an emerging global threat, and pan-resistance to current antifungal therapies is an increasing problem. clearly, there is a need for new antifungal drugs. in this study, we characterized a novel antifungal agent, the collismycin analog nr-6226c. nr-6226c has a favorable toxicity profile for human cells, which is essential for further clinical development. we unraveled the mechanism of action of nr-6226c and found that it disrupts iron homeostasis and thereby depletes fungal cells of energy. importantly, nr-6226c strongly potentiates the antifungal activity of fluconazole, thereby providing inroads for combination therapy that may reduce or prevent azole resistance. thus, nr-6226c is a promising compound for further development into antifungal treatment."}, {"Link/DOI": "https://doi.org/10.1101/2023.10.31.564956", "Publication Date": "2024-01-16 00:00:00", "Title": "the n6-methyladenosine demethylase alkbh5 regulates the hypoxic hbv transcriptome.", "ID Score": "0.9999794", "Team Score": "0.86141074", "Authors": "['Tsukuda, S.; Harris, J.; Magri, A.; Balfe, P.; Wing, P. A.; Siddiqui, A.; McKeating, J.']", "Abstract": "chronic hepatitis b is a global health problem and current treatments only suppress hepatitis b virus (hbv) infection, highlighting the need for new curative treatments. oxygen levels influence hbv replication and we previously reported that hypoxia inducible factors (hifs) activate the basal core promoter to transcribe pre-genomic rna. application of a probe-enriched long-read sequencing method to map the hbv transcriptome showed an increased abundance of all viral rnas under low oxygen or hypoxic conditions. importantly, the hypoxic-associated increase in hbv transcripts was dependent on n6-methyladenosine (m6a) modifications and an m6a drach motif in the 5 stem loop of pre-genomic rna defined transcript half-life under hypoxic conditions. given the essential role of m6a modifications in the viral transcriptome we assessed the oxygen-dependent expression of rna demethylases and bio-informatic analysis of published single cell rna-seq of murine liver showed an increased expression of the rna demethylase alkbh5 in the peri-central low oxygen region. in vitro studies with a human hepatocyte derived hepg2 cell line showed increased alkbh5 gene expression under hypoxic conditions. silencing the demethylase reduced the levels of hbv pre-genomic rna and host gene (ca9, ndrg1, vegfa, bnip3, fut11, gap and p4ha1) transcripts and this was mediated via reduced hif expression. in summary, our study highlights a previously unrecognized role for alkbh5 in orchestrating viral and cellular transcriptional responses to low oxygen.  author summaryoxygen levels influence hbv replication and hypoxia inducible factors (hifs) activate hbv transcription. long-read sequencing and mapping the hbv transcriptome showed an increased abundance of all viral rnas under hypoxic conditions that was dependent on n6-methyladenosine modifications. investigating the oxygen-dependent expression of rna demethylases identified alkbh5 as a hypoxic activated gene and silencing its expression showed a key role in regulating hbv and host gene expression under hypoxic conditions."}, {"Link/DOI": "https://doi.org/10.1101/2023.03.06.23286834", "Publication Date": "2024-01-16 00:00:00", "Title": "sars-cov-2 viral replication persists in the human lung for several weeks after onset of symptomatic severe covid-19 and is associated with attenuated pulmonary immunity and variant-specific clinical sequalae", "ID Score": "0.9999894", "Team Score": "0.93224645", "Authors": "['Tomasicchio, M.; Jaumdally, S.; Pooran, A.; Esmail, A.; Wilson, L.; Kotze, A.; Semple, L.; Meier, S.; Pillay, K.; Roberts, R.; Kriel, R.; Meldau, R.; Oelofse, S.; Mandviwala, C.; Burns, J.; Londt, R.; Davids, M.; van der Merwe, C.; Roomaney, A.; Kuhn, L.; Perumal, T.; Scott, A.; Hale, M.; Baillie, V.; Mahtab, S.; Williamson, C.; Joseph, R.; Sigal, A.; Joubert, I.; Piercy, J.; Thomson, D.; Fredericks, D.; Miller, M.; Nunes, M.; Madhi, S.; Dheda, K.']", "Abstract": "rationalein the upper respiratory tract replicating (culturable) sars-cov-2 is recoverable for [~] 4 to 8 days after symptom onset, however, there is paucity of data about the frequency or duration of replicating virus in the lower respiratory tract (i.e. the human lung).  objectiveswe undertook lung tissue sampling (needle biopsy), shortly after death, in 42 mechanically ventilated decedents during the beta and delta waves. an independent group of 18 ambulatory patents served as a control group.  methodslung biopsy cores from decedents underwent viral culture, histopathological analysis, electron microscopy, transcriptomic profiling and immunohistochemistry.  results38% (16/42) of mechanically ventilated decedents had culturable virus in the lung for a median of 15 days (persisting for up to 4 weeks) after symptom onset. lung viral culture positivity was not associated with comorbidities or steroid use. delta but not beta variant lung culture positivity was associated with accelerated death and secondary bacterial infection (p<0.05). nasopharyngeal culture was negative in 23.1% (6/26) of decedents despite lung culture positivity. this, hitherto, undescribed bio-phenotype of lung-specific persisting viral replication was associated with an enhanced transcriptomic pulmonary pro-inflammatory response but with concurrent viral culture positivity.  conclusionsconcurrent, rather than sequential active viral replication continues to drive a heightened pro-inflammatory response in the human lung beyond the second week of illness and was associated with variant-specific increased mortality and morbidity. these findings have potential implications for the design of interventional strategies and clinical management of patients with severe covid-19 disease.  at a glance commentaryo_st_absscientific knowledge on the subjectc_st_absinvestigations to understand sars-cov-2 viral shedding (determined by pcr or antigen testing) have extensively focused on samples from the upper respiratory tract. the widely accepted view is that acute severe sars-cov-2 infection is characterised by a viral replicative phase in the first week of symptomatic illness followed by a pro-inflammatory immunopathologic phase peaking in the second and third weeks of illness. however, it remains unclear whether detection of sars-cov-2 beyond 2 weeks after symptom onset in published studies represent active replication competent virus because it may represent residual genomic or antigenic material in the tissue.  what this study adds to the fieldwe have identified a, hitherto, undescribed bio-phenotype of acute severe covid-19 characterised by persisting viral replication in the lung for up to 4 weeks after symptom onset. [~]40% of acute severe covid-19 intensive care unit (icu) decedents (n=42) had nasopharyngeal swab culture positivity at [~]2 weeks post-symptom onset versus only [~]5% in a group of ambulatory control patients (n=18). there was compartment-specific (nasopharynx versus lung) discordance. the phenotype of lung-specific persisting viral replication was associated with variant-specific accelerated death, an exaggerated inflammatory response, and attenuated t-cell immunity in the lung (based on histopathological and transcriptomic studies). this challenges the traditional view that viral replication occurs during the first 5 to 10 days of illness, which is followed by an effector or hyperinflammatory phase. this is the first study, to our knowledge, to systematically culture virus from the human lung and map out its related clinical determinants, and which describes the human lung transcriptomic profile of culture-positive versus culture-negative patients with severe covid-19 disease."}, {"Link/DOI": "https://doi.org/10.1101/2023.11.14.23298501", "Publication Date": "2024-01-11 00:00:00", "Title": "tuberculosis-associated hemophagocytic lymphohistiocytosis: diagnostic challenges and determinants of outcome", "ID Score": "0.9999889", "Team Score": "0.9965442", "Authors": "['Kurver, L.; Seers, T.; van Dorp, S.; van Crevel, R.; Pollara, G.; van Laarhoven, A.']", "Abstract": "backgroundtuberculosis (tb) can induce secondary hemophagocytic lymphohistiocytosis (hlh), a severe inflammatory syndrome with high mortality. to improve insight into optimal diagnostic and treatment strategies, we integrated all published reports of adult hiv-negative tb-associated hlh (tb-hlh) globally to define clinical characteristics and therapeutic approaches associated with improved survival.  methodspubmed, embase, and global index medicus were searched for eligible records. tb-hlh cases were categorized into patients with a confirmed tb diagnosis receiving antituberculosis treatment while developing hlh, and patients presenting with hlh of unknown cause later diagnosed with tb. we integrated patients clinical characteristics, diagnostic test results, and pre-specified parameters associated with survival into a logistic regression model.  resultswe identified 115 individually reported cases, 45 (39.1%) from low tb incidence countries (<10/100.000 per year). compared to hlh patients with known tb (n=21), patients with hlh of unknown cause (n=94), more often had extrapulmonary tb (88.3% vs. 66.7%), while the opposite was true for pulmonary disease (59.6% vs. 91.5%). overall, mycobacterium tuberculosis was identified in the bone marrow in 78.4% of patients for whom examination was reported (n=74). only 10.5% (4/38) of patients tested had a positive tuberculin skin test or interferon gamma release assay. in-hospital survival was 71.9% (69/96) in those treated for tb and 0% (18/18) in those who did not receive antituberculosis treatment (p < 0.001).  conclusionstuberculosis should be considered as a cause of unexplained hlh. tb-hlh is probably under-reported, and the diagnostic work-up of hlh patients should include bone marrow examination for evidence of m. tuberculosis infection. prompt initiation of antituberculosis treatment will likely improve survival.  key pointshemophagocytic lymphohistiocytosis is an underreported complication of tuberculosis, often manifesting as extrapulmonary or miliary disease. tst and igra mostly show an anergic response. threshold should be low bone marrow investigation for evidence of m. tuberculosis, and commencement of antituberculosis treatment."}, {"Link/DOI": "https://doi.org/10.1101/2023.06.20.545750", "Publication Date": "2024-01-10 00:00:00", "Title": "drug resistance without a cost? common and uncommon routes to fosfomycin resistance in uropathogenic escherichia coli", "ID Score": "0.99992776", "Team Score": "0.9410844", "Authors": "['Bermudez, T.; Brannon, J. R.; Dudipala, N.; Reasoner, S.; Morales, G. H.; Wiebe, M. A.; Cecala, M.; Beebout, C. J.; Amir, O.; Hadjifrangiskou, M.']", "Abstract": "fosfomycin kills bacteria by blocking the binding of phosphoenolpyruvate (pep) to the bacterial enzyme mura and halting peptidoglycan synthesis. while its use has increased with the emergence of antibiotic resistance, the mechanisms leading to fosfomycin resistance remain relatively unexplored. in uropathogenic escherichia coli (upec) that accounts for >75% of urinary tract infections (utis), fosfomycin enters the cell primarily through uhpt, which transports glucose-6-phosphate (g6p) glycolysis intermediate into the cell. mutations in uhpt lead to fosfomycin resistance and have been identified during antimicrobial susceptibility testing (ast) in non-susceptible inner colonies that form within the zone of inhibition. however, eucast and clsi guidelines differ in how to read fosfomycin ast when such resistant colonies arise. work from our lab and others demonstrated that glycolysis is dispensable during acute uti. moreover, g6p is scarce in urine, prompting us to test the hypothesis that uhp mutations may not impart a fitness cost to the pathogen. we report that loss of uhp indeed does not impair upec pathogenesis and that clinical isolates exist that lack the uhp locus altogether. analysis of non-susceptible inner colonies revealed a suite of novel genes involved in fosfomycin resistance. one of them is pykf that converts pep to pyruvate during glycolysis. single deletions of pykf or its anaerobic homolog pyka do not attenuate upec. based on our data, we raise the alarm that multiple routes lead to fosfomycin resistance and do not affect pathogenesis and propose that the current eucast and clsi guidelines unify into how they evaluate fosfomycin ast.  importancewhile fosfomycin resistance is rare, the observation of non-susceptible subpopulations among clinical escherichia coli isolates is a common phenomenon during antimicrobial susceptibility testing (ast) in american and european clinical labs. previous evidence suggests that mutations eliciting this phenotype are of high biological cost to the pathogen during infection, leading to current recommendations of neglecting non-susceptible colonies during ast. here we report that the most common route to fosfomycin resistance, as well as novel routes described in this work do not impair virulence in uropathogenic e. coli, the major cause of urinary tract infections, suggesting a re-evaluation of current susceptibility guidelines is warranted."}, {"Link/DOI": "https://doi.org/10.1101/2023.05.23.541932", "Publication Date": "2024-01-10 00:00:00", "Title": "accelerated prime-and-trap vaccine regimen in mice using reprna-based csp malaria vaccine", "ID Score": "0.9999856", "Team Score": "0.875111", "Authors": "['MacMillen, Z.; Hatzakis, K.; Simpson, A.; Shears, M. J.; Watson, F.; Erasmus, J.; Khandhar, A. P.; Wilder, B. K.; Murphy, S. C.; Reed, S. G.; Davie, J. W.; Avril, M.']", "Abstract": "malaria, caused by plasmodium parasites, remains one of the most devastating infectious diseases worldwide, despite control efforts that have lowered morbidity and mortality. the only p. falciparum vaccine candidates to show field efficacy are those targeting the asymptomatic pre-erythrocytic (pe) stages of infection. the subunit (su) rts,s/as01 vaccine, the only licensed malaria vaccine to date, is only modestly effective against clinical malaria. both rts,s/as01 and the su r21 vaccine candidate target the pe sporozoite (spz) circumsporozoite (cs) protein. these candidates elicit high-titer antibodies that provide short-term protection from disease, but do not induce the liver-resident memory cd8+ t cells (trm) that confer strong pe immunity and long-term protection. in contrast, whole-organism (wo) vaccines, employing for example radiation-attenuated spz (ras), elicit both high antibody titers and trm, and have achieved high levels of sterilizing protection. however, they require multiple intravenous (iv) doses, which must be administered at intervals of several weeks, complicating mass administration in the field. moreover, the quantities of spz required present production difficulties. to reduce reliance on wo while maintaining protection via both antibodies and trm responses, we have developed an accelerated vaccination regimen that combines two distinct agents in a prime-and-trap strategy. while the priming dose is a self-replicating rna encoding p. yoelii cs protein, delivered via an advanced cationic nanocarrier (liontm), the trapping dose consists of wo ras. this accelerated regime confers sterile protection in the p. yoelii mouse model of malaria. our approach presents a clear path to late-stage preclinical and clinical testing of dose-sparing, same-day regimens that can confer sterilizing protection against malaria."}, {"Link/DOI": "https://doi.org/10.1101/2023.03.15.23287300", "Publication Date": "2024-01-10 00:00:00", "Title": "risk factors for sars-cov-2 infection: a test-negative case-control study with additional population controls", "ID Score": "0.9999893", "Team Score": "0.97345066", "Authors": "['Sarjomaa, M.; Zhang, C.; Tveten, Y.; Kersten, H.; Reiso, H.; Eikeland, R.; Kongerud, J.; Berg, K. K.; Thilesen, C.; Nordbo, S. A.; Aaberge, I.; Vandenbroucke, J.; Pearce, N.; Fell, A. K.']", "Abstract": "objectivesto assess risk factors for sars-cov-2 infection by first comparing positive cases with negative controls as determined by polymerase chain reaction (pcr) testing and then comparing these two groups with an additional population control group.  design and settingtest-negative design (tnd), multicentre case-control study with additional population controls in south eastern norway.  participantsadults who underwent sars-cov-2 pcr testing between february and december 2020. pcr-positive cases, pcr-negative controls, and additional age-matched population controls.  primary outcome measuresthe associations between various risk factors based on self-reported questionnaire and sars-cov-2 infection comparing pcr positive cases and pcr-negative controls. using subgroup analysis, the risk factors were then compared with a population control group. univariate and multivariate regression analyses were performed.  resultsin total, 400 sars-cov-2 pcr-positive cases, 719 pcr-negative controls, and 14,509 population controls were included. male sex was associated with the risk of sars-cov-2 infection when pcr-positive cases were compared with pcr-negative controls (or 1.9, 95% ci 1.4 to 2.6). age, education level, comorbidities (asthma, diabetes, hypertension), an exercise were not associated with the risk of sars-cov-2 infection when pcr-positive cases were compared with pcr-negative controls. in the subgroup analysis comparing pcr-positive cases with age-matched population controls, asthma was associated with the risk of sars-cov-2 infection (or 1.6, 95% ci 1.1 to 2.1). daily or occasional smoking was negatively associated with the risk of sars-cov-2 infection in both analyses (or 0.5, 95% ci 0.3 to 0.8 and or 0.55, 95% ci 0.35, to 0.82, respectively).  conclusionsmale sex was a possible risk factor, whereas smoking was negatively associated with the risk of sars-cov-2 infection, when comparing pcr-positive cases and pcr-negative controls. asthma was associated with the risk of sars-cov-2 infection when pcr-positive cases were compared with population controls.  article summaryo_st_absstrengths and limitations of this studyc_st_abso_lithe test-negative design (tnd) was an important strength of this study. the design can reduce confounding from healthcare-seeking bias because pcr-controls are likely to have similar healthcare-seeking attitudes as pcr+ cases. c_lio_lithis study mostly included non-hospitalised patients, which can improve the generalisability of the findings to the general public. c_lio_lithe use of an additional control group from the general public for comparison with the findings from the test-negative controls provides further information on the similarities and differences in risk factors for covid-19 and other respiratory tract infections. c_lio_liin the subgroup analyses, pcr+ cases and pcr- controls were compared with the population controls to assess the risk factors for those aged 18-55 years. hence, the results may not be generalisable to patients older than 55 years. c_lio_lipcr test results, rather than symptoms, were used to categorise the participants into cases or controls, and therefore risk factors for sars-cov-2 infection and not covid-19 disease were assessed. c_li"}, {"Link/DOI": "https://doi.org/10.1101/2023.04.17.536908", "Publication Date": "2024-01-09 00:00:00", "Title": "conversion of monoclonal igg to dimeric and secretory iga restores neutralizing ability and prevents infection of omicron lineages", "ID Score": "0.99998844", "Team Score": "0.92172134", "Authors": "['Marcotte, H.; Cao, Y.; Zuo, F.; Simonelli, L.; Sammartino, J. C.; Pedotti, M.; Sun, R.; Cassaniti, I.; Hagbom, M.; Piralla, A.; Yang, J.; Du, L.; Percivalle, E.; Bertoglio, F.; Schubert, M.; Abolhassani, H.; Sherina, N.; Guerra, C.; Borte, S.; Razaei, N.; Kumagai-Braesch, M.; Xue, Y.; Gronwall, C.; Klareskog, L.; Calzolai, L.; Cavalli, A.; Wang, Q.; Robbiani, D. F.; Hust, M.; Shi, Z.; Feng, L.; Svensson, L.; Chen, L.; Bao, L.; Baldanti, F.; Qin, C.; Xiao, J.; Hammarstrom, L.; Yang, X. L.; Varani, L.; Sunney Xie, X.; Pan-Hammarstrom, Q.']", "Abstract": "the emergence of omicron lineages and descendent subvariants continues to present a severe threat to the effectiveness of vaccines and therapeutic antibodies. we have previously suggested that an insufficient mucosal iga response induced by the mrna vaccines is associated with a surge in breakthrough infections. here, we further show that the intramuscular mrna and/or inactivated vaccines cannot sufficiently boost the mucosal siga response in uninfected individuals, particularly against the omicron variant. we thus engineered and characterized recombinant monomeric, dimeric and secretory iga1 antibodies derived from four neutralizing igg monoclonal antibodies targeting the receptor-binding domain of the spike protein (01a05, rmab23, dxp-604 and xg014). compared to their parental igg antibodies, dimeric and secretory iga1 antibodies showed a higher neutralizing activity against different variants of concern (vocs), in part due to an increased avidity. importantly, the dimeric or secretory iga1 form of the dxp-604 antibody significantly outperformed its parental igg antibody, and neutralized the omicron lineages ba.1, ba.2 and ba.4/5 with a 50-150-fold increase in potency, reaching the level of the most potent monoclonal antibodies described till date. in hace2 transgenic mice, a single intranasal dose of the dimeric iga dxp-604 conferred prophylactic and therapeutic protection against omicron ba.5. conversion of iga and dimerization further enhanced or restored the neutralizing ability against the emerging omicron sub-variants (dxp-604 for bq.1, bq.1.1 and ba2.75; 01a05 for ba2.75, ba.2.75.2 and xbb.1). thus, dimeric or secretory iga delivered by nasal administration may potentially be exploited for the treatment and prevention of omicron infection, thereby providing an alternative tool for combating immune evasion by subvariants and, potentially, future vocs.  one sentence summaryengineered dimeric and secretory iga1 neutralized omicron variant with higher potency than parental igg."}, {"Link/DOI": "https://doi.org/10.1101/2021.10.20.465232", "Publication Date": "2024-01-09 00:00:00", "Title": "a recombinant multivalent vaccine (rcpa1) induces protection for c57bl/6 and hla transgenic mice against pulmonary infection with both species of coccidioides", "ID Score": "0.9999887", "Team Score": "0.97383887", "Authors": "['Campuzano, A.; Pentakota, K. D.; Liao, Y.-R.; Zhang, H.; Wiederhold, N. P.; Ostroff, G.; Hung, C.-Y.']", "Abstract": "coccidioidomycosis is caused by coccidioides posadasii (cp) and coccidioides immitis (ci) that have 4-5% differences in their genomic sequences. there is an urgent need to develop a human vaccine against both species. a previously created recombinant antigen (rcpa1) that contains multiple peptides derived from cp isolate c735 is protective against the autologous isolate. the focus of this study is to evaluate cross-protective efficacy and immune correlates by the rcpa1- based vaccine against both species of coccidioides. dna sequence analyses of the homologous genes for the rcpa1 antigen were conducted for 39 and 17 clinical isolates of cp and ci, respectively. protective efficacy and vaccine-induced immunity were evaluated for both c57bl/6 and human hla-dr4 transgenic mice against 5 highly virulent isolates of cp and ci. there are a total of 7 amino acid substitutions in the rcpa1 antigen between cp and ci. both c57bl/6 and hla-dr4 mice that were vaccinated with a rcpa1 vaccine resulted in significant reduction of fungal burden and increased numbers of ifn-{gamma}- and il-17-producing cd4+ t cells in the first 2 weeks post-challenge. these data support that rcpa1 has cross-protection activity against cp and ci pulmonary infection through activation of early th1 and th17 responses."}, {"Link/DOI": "https://doi.org/10.1101/2023.06.15.23291261", "Publication Date": "2024-01-09 00:00:00", "Title": "rapid nanopore metagenomic sequencing and predictive susceptibility testing of positive blood cultures from intensive care patients with sepsis", "ID Score": "0.9999882", "Team Score": "0.89695656", "Authors": "['Harris, P. N. A.; Bauer, M. J.; Lueftinger, L.; Beisken, S.; Forde, B. M.; Balch, R.; Cotta, M. O.; Schlapbach, L.; Raman, S.; Shekar, K.; Kruger, P.; Lipman, J.; Bialasiewicz, S.; Coin, L. J. M.; Roberts, J. A.; Paterson, D. L.; Irwin, A. D.']", "Abstract": "backgrounddirect metagenomic sequencing from positive blood culture (bc) broths, to identify bacteria and predict antimicrobial susceptibility, has been previously demonstrated using illumina-based methods, but is relatively slow. we aimed to evaluate this approach using nanopore sequencing to provide more rapid results.  methodspatients with suspected sepsis in 4 intensive care units were prospectively enrolled. human-depleted dna was extracted from positive bc broths and sequenced using nanopore (minion). species abundance was estimated using kraken2, and a cloud-based artificial intelligence (ai) system (arescloud) provided in silico antimicrobial susceptibility testing (ast) from assembled contigs. these results were compared to conventional identification and phenotypic ast.  resultsgenus-level agreement between conventional methods and metagenomic whole genome sequencing (mg-wgs) was 96.2% (50/52), but increased to 100% in monomicrobial infections. in total, 262 high quality arescloud ast predictions across 24 samples were made, exhibiting categorical agreement (ca) of 89.3%, with major error (ma) and very major error (vme) rates of 10.5% and 12.1%, respectively. over 90% ca was achieved for some taxa (e.g. staphylococcus aureus), but was suboptimal for pseudomonas aeruginosa (ca 50%). in 470 ast predictions across 42 samples, with both high quality and exploratory-only predictions, overall ca, me and vme rates were 87.7%, 8.3% and 28.4%. vme rates were inflated by false susceptibility calls in a small number of species / antibiotic combinations with few representative resistant isolates. time to reporting from mg-wgs could be achieved within 8-16 hours from blood culture positivity.  conclusionsdirect metagenomic sequencing from positive bc broths is feasible and can provide accurate predictive ast for some species and antibiotics, but is sub-optimal for a subset of common pathogens, with unacceptably high vme rates. nanopore-based approaches may be faster but improvements in accuracy are required before it can be considered for clinical use. new developments in nanopore sequencing technology, and training of ai algorithms on larger and more diverse datasets may improve performance."}, {"Link/DOI": "https://doi.org/10.1101/2023.10.03.23296486", "Publication Date": "2024-01-09 00:00:00", "Title": "repeat testing of mpox specimens with late cts improves detection of potential false positive cases", "ID Score": "0.99998987", "Team Score": "0.98583096", "Authors": "['Shean, R.; Hymas, W.; Klein, J.; Pyne, M. T.; Hillyard, D.; Bradley, B. T.']", "Abstract": "the global outbreak of mpox necessitated the rapid development of clinical assays for monkeypox virus detection. while the majority of mpox specimens have high viral loads with corresponding early ct values, reports have indicated some specimens with late ct values can represent false positive results. to mitigate this risk, the centers for disease control and prevention (cdc) published an advisory recommending repeat testing of all specimens with ct values [&ge;]34. however, limited experimental data was available to support this specific cutoff. in this study, we examine whether a more conservative approach in which all specimens with ct values [&ge;]29 are repeated would improve the detection of potential false positive results. compared to the cdc algorithm, our approach identified an additional 20% (5/25) of potential false positive results. to assess the impact of this cutoff on laboratory workload, we estimated the expected increase in test volume and turnaround time (tat) relative to the cdc method. using a lower repeat threshold, test volume increased by 0.7% and the mean tat for positive specimens increased by less than 15 minutes. overall, a lower threshold than recommended by the cdc for repeating late ct mpox specimens may reduce the number of false positives reported while minimally impacting testing volume and tat."}, {"Link/DOI": "https://doi.org/10.1101/2020.06.24.20138941", "Publication Date": "2024-01-09 00:00:00", "Title": "co-occurrence of sars-cov-2 and respiratory pathogens in the frail elderly", "ID Score": "0.99998987", "Team Score": "0.9394955", "Authors": "['Baunoch, D.; Wolfe, A.; Wang, D.; Gnewuch, R.; Zhao, X.; Halverson, T.; Cacdac, P.; Huang, S.; Lauterbach, T.; Luke, N.']", "Abstract": "backgroundelderly sars-cov-2 patients are associated with higher hospitalization and mortality. co-infection is critical in the severity of respiratory diseases. it is largely understudied for sars-cov-2.  methodsbetween march 24th and april 27th, 2020, nasopharyngeal and oropharyngeal swabs from 3,348 patients from nursing homes and assisted living facilities in 22 states in the us were tested by capstone healthcare for sars-cov-2, 24 other respiratory viruses, and 8 respiratory bacteria. total nucleic acid was extracted with magmax viral/pathogen ultra nucleic acid isolation kit. sars-co-v-2 was detected with the cdc 2019-novel coronavirus (2019-ncov) diagnostic panel. total nucleic acid was pre-amplified before analysis for other respiratory pathogens with taqman openarray respiratory tract microbiota plate.  resultspatients mean age was 76.9 years. sars-cov-2 was detected in 1,413 patients (42.2%). among them, 1,082 (76.6%) and 737 (43.7%) patients were detected with at least one bacterium or another virus, respectively. sars-cov-2-positive patients were more likely to have bacterial co-occurrences (76.6%) than sars-cov-2-negative patients (70.0%) (p<0.0001). the most common co-occurring bacteria were staphylococcus aureus and klebsiella pneumonia, detected in 55.8% and 40.1% sars-cov-2-positive patients, respectively. staphylococcus aureus was associated with sars-cov-2, with higher detection rates in sars-cov-2-positive patients (55.8%) than sars-cov-2-negative patients (46.2%) (p<0.0001). human herpes virus 6 (hhv6) also was common and associated with sars-cov-2, with higher detection rates in sars-cov-2-positive patients (26.6%) than sars-cov-2-negative patients (19.1%) (p<0.0001).  conclusionssars-cov-2-positive patients are more likely to be positive for certain respiratory bacteria and viruses. this observation may help explain high hospitalization and mortality rates in older patients."}, {"Link/DOI": "https://doi.org/10.1101/2022.11.09.22282142", "Publication Date": "2024-01-09 00:00:00", "Title": "assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of covid-19", "ID Score": "0.9999895", "Team Score": "0.9915671", "Authors": "['Sidky, H.; Sahner, D. K.; Girvin, A. T.; Hotaling, N.; Michael, S. G.; Kurilla, M. G.; Gersing, K.; The N3C consortium,  ']", "Abstract": "importancepost-acute sequelae of covid-19 (pasc) produce significant morbidity, prompting evaluation of interventions that might lower risk. selective serotonin reuptake inhibitors (ssris) potentially could modulate risk of pasc via their central, hypothesized immunomodulatory, and/or antiplatelet properties and therefore may be postulated to be of benefit in patients with pasc, although clinical trial data are lacking.  objectivesthe main objective was to evaluate whether ssris with agonist activity at the sigma-1 receptor lower the risk of pasc, since agonism at this receptor may serve as a mechanism by which ssris attenuate an inflammatory response. a secondary objective was to determine whether potential benefit could be traced to sigma-1 agonism by evaluating the risk of pasc among recipients of ssris that are not s1r agonists.  designretrospective study leveraging real-world clinical data within the national covid cohort collaborative (n3c), a large centralized multi-institutional de-identified ehr database. presumed pasc was defined based on a computable pasc phenotype trained on the u09.9 icd-10 diagnosis code to more comprehensively identify patients likely to have the condition, since the icd code has come into wide-spread use only recently.  settingpopulation-based study at us medical centers.  participantsadults ([&ge;] 18 years of age) with a confirmed covid-19 diagnosis date between october 1, 2021 and april 7, 2022 and at least one follow up visit 45 days post-diagnosis. of the 17 933 patients identified, 2021 were exposed at baseline to a s1r agonist ssri, 1328 to a non-s1r agonist ssri, and 14 584 to neither.  exposuresexposure at baseline (at or prior to covid-19 diagnosis) to an ssri with documented or presumed agonist activity at the s1r (fluvoxamine, fluoxetine, escitalopram, or citalopram), an ssri without agonist activity at s1r (sertraline, an antagonist, or paroxetine, which does not appreciably bind to the s1r), or none of these agents.  main outcome and measurementdevelopment of pasc based on a previously validated xgboost-trained algorithm. using inverse probability weighting and poisson regression, relative risk (rr) of pasc was assessed.  resultsa 26% reduction in the rr of pasc (0.74 [95% ci, 0.63-0.88]; p = 5 x 10-4) was seen among patients who received an s1r agonist ssri compared to ssri unexposed patients and a 25% reduction in the rr of pasc was seen among those receiving an ssri without s1r agonist activity (0.75 [95% ci, 0.62 - 0.90]; p = 0.003) compared to ssri unexposed patients.  conclusions and relevancessris with and without reported agonist activity at the s1r were associated with a significant decrease in the risk of pasc. future prospective studies are warranted.  key pointso_st_absquestionc_st_absdo selective serotonin reuptake inhibitors with and without agonist activity at the sigma-1 receptor (s1r) prevent post-acute sequelae of covid-19?  findingsin this retrospective study leveraging real-world clinical data that included 17 933 patients, a 28% reduction in risk of pasc was observed for s1r agonist ssris and a 25% reduction in risk of pasc was observed for non-s1r agonist ssris, both versus controls, using a computable phenotype to define pasc.  meaningssris may play a role in managing the long term disease burden of covid-19. future prospective studies are warranted to confirm these findings and evaluate potential mechanisms of action."}, {"Link/DOI": "https://doi.org/10.1101/2023.09.11.557146", "Publication Date": "2024-01-08 00:00:00", "Title": "suppression of progesterone by influenza a virus causes adverse maternal and fetal outcomes in mice", "ID Score": "0.9999143", "Team Score": "0.9046232", "Authors": "['Creisher, P. S.; Parish, M. A.; Lei, J.; Liu, J.; Perry, J. L.; Campbell, A. D.; Sherer, M. L.; Burd, I.; Klein, S. L. L.']", "Abstract": "influenza a virus infection during pregnancy can cause adverse maternal and fetal outcomes, but the mechanism responsible remains elusive. infection of outbred mice with 2009 h1n1 at embryonic day (e) 10 resulted in significant maternal morbidity, placental tissue damage and inflammation, fetal growth restriction, and developmental delays that lasted through weaning. restriction of pulmonary virus replication was not inhibited during pregnancy, but infected dams had suppressed circulating and placental progesterone (p4) concentrations that were caused by h1n1-induced upregulation of pulmonary cyclooxygenase (cox)-1, but not cox-2-, dependent synthesis and secretion of prostaglandin (pg) f2. treatment with 17--hydroxyprogesterone caproate (17-ohpc), a synthetic progestin that is safe to use in pregnancy, ameliorated the adverse maternal and fetal outcomes from h1n1 infection and prevented placental cell death and inflammation. these findings highlight the therapeutic potential of progestin treatments for influenza during pregnancy.  importancepregnant individuals are at risk of severe outcomes from both seasonal and pandemic influenza a viruses. influenza infection during pregnancy is associated with adverse fetal outcomes at birth and adverse consequences for offspring into adulthood. we developed an outbred mouse model of 2009 h1n1 influenza virus infection during pregnancy, with semi-allogenic fetuses. when dams are infected with 2009 h1n1, in addition to pulmonary virus replication, tissue damage, and inflammation, the placenta shows evidence of transient damage and inflammation that is mediated by increased activity along the arachidonic acid pathway leading to suppression of circulating progesterone. placental damage and suppressed progesterone are associated with long-term effects on perinatal growth and developmental delays in offspring. treatment of h1n1-infected pregnant mice with 17-ohpc, a synthetic progestin treatment safe that is safe to use in pregnancy, prevents placental damage and inflammation and adverse fetal outcomes. this provided a novel therapeutic option for treatment of influenza during pregnancy that should be explored clinically."}, {"Link/DOI": "https://doi.org/10.1101/2023.09.02.556065", "Publication Date": "2024-01-08 00:00:00", "Title": "differential susceptibility of human microglia hmc3 cells and brain microvascular endothelial hbec-5i cells to mayaro and una virus infection", "ID Score": "0.99981457", "Team Score": "0.89397126", "Authors": "['Campos, D.; Sugasti-Salazar, M.; Galan-Jurado, P. E.; Valdes-Torres, P.; Zegarra, D.; Gonzalez Santamaria, J.']", "Abstract": "mayaro (mayv) and una (unav) are emerging alphaviruses circulating in the americas. earlier reports have revealed that mayv infects different human cell lines, including synovial and dermal fibroblasts, chondrocytes, osteoblasts, astrocytes and pericytes, as well as neural progenitor cells. in this study we evaluated the susceptibility of immortalized human microglia hmc3 cells and brain microvascular endothelial hbec-5i cells to mayv and unav infection. cytopathic effects, cell viability, viral progeny yields, and the presence of e1 and nsp1 proteins in hmc3 and hbec-5i cells infected with several mayv or unav strains were assessed using an inverted microscope, mtt assay, plaque-forming assays, and immunofluorescence or western blot, respectively. finally, the expression of immune response genes was analyzed using qrt-pcr. mayv and unav demonstrated strong cytopathic effects and significantly reduced cell viability in hmc3 cells. moreover, the hmc3 cells were efficiently infected regardless of the virus strains tested, and e1 and nsp1 viral proteins were detected. in contrast, only mayv appeared to infect hbec-5i cells, and minimal effects on cell morphology or viability were observed. furthermore, the mayv titer and viral protein levels were substantially lower in the infected hbec-5i cells when compared to those of the infected microglia cells. finally, unlike unav, mayv elicited a strong expression of specific interferon-stimulated genes in microglia cells, along with pro-inflammatory cytokines implicated in the immune response. collectively, these findings demonstrate that mayv and unav are capable of infecting relevant human brain cells."}, {"Link/DOI": "https://doi.org/10.1101/2023.09.08.23295262", "Publication Date": "2024-01-03 00:00:00", "Title": "comparison of covid-19 and influenza-related outcomes in the united states during fall-winter 2022-2023", "ID Score": "0.9999895", "Team Score": "0.8659868", "Authors": "['Kopel, H.; Bogdanov, A.; Winer-Jones, J.; Adams, C.; Winer, I.; Bonafede, M.; Nguyen, V. H.; Mansi, J. A.']", "Abstract": "backgroundthree years into the pandemic, sars-cov-2 remains a significant burden in comparison to other respiratory illnesses; however, many of the monitoring tools available during the early phase of the covid-19 pandemic have been phased out, making it more difficult to track the current burden of outpatient medical encounters and hospitalizations, especially for at-risk groups. the objective of this analysis was to characterize the frequency and severity of medically-attended covid-19 and influenza during peak influenza activity in the pediatric (0-17), adult (18-64), and older adult (65+) populations and characterize the prevalence of underlying medical conditions among patients hospitalized with covid-19.  methodsthis was a cross-sectional analysis of individuals in the veradigm health insights ehr database linked to komodo claims data with a medical encounter of claim between october 1, 2022, and march 31, 2023. we captured age, sex, and underlying medical conditions associated with higher risk for severe covid-19 during a 12-month baseline period. we identified patients with medical encounters with a diagnosis of covid-19 or influenza between october 1, 2022, and march 31, 2023, and stratified them into 5 mutually exclusive categories based on the highest level of care received with that diagnosis during the season (intensive care unit [icu] > hospitalization without icu > emergency department > urgent care > other outpatient).  resultsamong the 23,526,196 individuals in the dataset, 5.0% had a covid-19-related medical encounter, and 3.0% had an influenza-related medical encounter during the 6 month observation period. the incidence of hospitalizations with a covid-19 diagnosis was 4.6 times higher than the incidence of hospitalizations with an influenza diagnosis. hospitalizations with covid-19 were higher in all age groups. nearly all adults hospitalized with covid-19 had at least one underlying medical condition, but 25.8% of 0-5-year-olds and 18.3% of 6-17-year-olds had no underlying medical conditions.  conclusionscovid-19 continues to place a heavy burden on the united states healthcare system and was associated with more medical encounters in all age groups, including hospitalizations, than influenza during a 6-month period that included the 2022-2023 peak influenza activity."}, {"Link/DOI": "https://doi.org/10.1101/2023.09.01.23293947", "Publication Date": "2024-01-03 00:00:00", "Title": "pulmonary function and survival one year after dupilumab treatment of acute moderate to severe covid-19: a follow up study from a phase iia trial", "ID Score": "0.9999896", "Team Score": "0.99318355", "Authors": "['Hendrick, J.; Ma, J. Z.; Haughey, H. M.; Coleman, R.; Nayak, U.; Kadl, A.; Sturek, J. M.; Jackson, P.; Young, M. K.; Allen, J. E.; Petri, W. A.']", "Abstract": "backgroundwe previously conducted a phase iia randomized placebo-controlled trial of 40 subjects to assess the efficacy and safety of dupilumab use in those hospitalized with covid-19 (nct04920916). based on our pre-clinical data suggesting downstream pulmonary dysfunction with covid-19 induced type 2 inflammation, we contacted patients from our phase iia study at 1 year for assessment of post covid-19 conditions (pcc).  methodssubjects at 1 year after treatment underwent pulmonary function testing (pfts), high resolution computed tomography (hrct) imaging, symptom questionnaires, neurocognitive assessments, and serum immune biomarker analysis, with subject survival also monitored. the primary outcome was the proportion of abnormal pfts, defined as an abnormal diffusion capacity for carbon monoxide (dlco) or 6-minute walk testing (6mwt) at the 1-year visit.  resultssixteen of the 29 one-year survivors consented to the follow up visit. we found that subjects who had originally received dupilumab were less likely to have abnormal pfts compared to those who received placebo (fishers exact p=0.011, adjusted p=0.058). we additionally found that 3 out of 19 subjects (16%) in the dupilumab group died by 1 year compared to 8 out of 21 subjects (38%) in the placebo group (log rank p=0.12). we did not find significant differences in neurocognitive testing, symptoms or ct chest imaging between treatment groups but observed evidence of reduced type 2 inflammation in those who received dupilumab.  conclusionswe observed evidence of reduced long-term morbidity and mortality from covid-19 with dupilumab treatment during acute hospitalization when added to standard of care regimens."}, {"Link/DOI": "https://doi.org/10.1101/2022.02.11.480131", "Publication Date": "2024-01-02 00:00:00", "Title": "omicron-based vaccine candidate elicits potent neutralizing antibodies in the animal model", "ID Score": "0.99880564", "Team Score": "0.9897014", "Authors": "['Abdoli, A.; Khanali, J.; Azangou-Khyavy, M.; Abbasi-Kangevari, M.; Ghamari, S.-H.; Malekpour, M.-R.; Jamshidi, H.; Lari Baghal, M.; Taqavian, M.; Jalili, H.']", "Abstract": "backgroundomicron variant (b. 1.1.529) is able to escape from naturally acquired and vaccine-induced immunity, which mandates updating the current covid-19 vaccines. here, we investigated and compared the neutralising antibody induction of the ancestral variant-based biv1-coviran vaccine, the omicron variant-based biv1-coviran plus vaccine, and the novel bivalent vaccine candidate, bbiv1-coviran, against the omicron and ancestral wuhan variants on the rat model.  methodsviruses were isolated from a clinical specimen and virus characterisation performed. after inactivating the viral particles, the viruses were purified and formulated. bivalent vaccines were a composition of 2.5 g (5 g total) or 5 g (10 g total) doses of each ansectral-based and omicron-based monovalent vaccine. subsequently, the potency of the monovalent and bivalent vaccines was investigated using the virus neutralisation test (vnt).  resultsthe group that received three doses of the omicron-specific vaccine demonstrated neutralisation activity against the omicron variant with a geometric mean titer of 337.8. however, three doses of the wuhan variant-specific vaccine could neutralise the omicron variant at a maximum of 1/32 serum dilution. the neutralisation activity of the omicron-specific vaccine, when administered as the booster dose after two doses of the wuhan variant-specific vaccine, was 100% against the omicron variant and the wuhan variant at 1/64 and 1/128 serum dilution, respectively. three doses of 5 g bivalent vaccine could effectively neutralise both variants at the minimum of 1/128 serum dilution. the 10 g bivalent vaccine at three doses showed even higher neutralisation titers: geometric mean titer of 338.0 against omicron and 445.7 against wuhan).  conclusionit is shown that the candidate bivalent vaccine could elicit a potent immune response against both wuhan-hu-1 and omicron ba.1 variants. therefore, we plan to evaluate the updated vaccine in the clinical trial setting."}, {"Link/DOI": "https://doi.org/10.1101/2023.09.21.23295701", "Publication Date": "2024-01-02 00:00:00", "Title": "detection of anti-premembrane antibody as a specific marker of four flavivirus serocomplexes and its application to serosurveillance in endemic regions", "ID Score": "0.9999896", "Team Score": "0.81779647", "Authors": "['Chen, G.-H.; Dai, Y.-C.; Hsieh, S.-C.; Tsai, J.-J.; Sy, A.; Jiz, M.; Petroso, C.; Brites, C.; Netto, E.; Kanki, P. J.; Saundersi, D.; Vanlandingham, D.; Higgs, S.; Huang, Y.-J.; Wang, W.-K.']", "Abstract": "in the past few decades, several emerging/re-emerging mosquito-borne flaviviruses have resulted in disease outbreaks of public health concern in the tropics and subtropics. due to cross-reactivities of antibodies recognizing the envelope protein of different flaviviruses, serosurveillance remains a challenge. previously we reported that anti-premembrane (prm) antibody can discriminate between three flavivirus infections by western blot analysis. in this study, we aimed to develop a serological assay that can discriminate infection or exposure with flaviviruses from four serocomplexes, including dengue (denv), zika (zikv), west nile (wnv) and yellow fever (yfv) viruses, and explore its application for serosurveillance in flavivirus-endemic countries. we employed western blot analysis including antigens of six flaviviruses (denv1, 2 and 4, wnv, zikv and yfv) from four serocomplexes. we tested serum samples from yf-17d vaccinees, and from denv, zikv and wnv panels that had been confirmed by rt-pcr or by neutralization assays. the overall sensitivity/specificity of anti-prm antibodies for denv, zikv, wnv, and yfv infections/exposure were 91.7%/96.4%, 91.7%/99.2%, 88.9%/98.3%, and 91.3%/92.5%, respectively. when testing 48 samples from brazil, we identified multiple flavivirus infections/exposure including denv and zikv, denv and yfv, and denv, zikv and yfv. when testing 50 samples from the philippines, we detected denv, zikv, and denv and zikv infections with a zikv seroprevalence rate of 10%, which was consistent with reports of low-level circulation of zikv in asia. together, these findings suggest that anti-prm antibody is a flavivirus serocomplex-specific marker and can be employed to delineate four flavivirus infections/exposure in regions where multiple flaviviruses co-circulate."}, {"Link/DOI": "https://doi.org/10.1101/2023.06.20.545832", "Publication Date": "2023-12-30 00:00:00", "Title": "combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in severe covid-19", "ID Score": "0.9999896", "Team Score": "0.82549965", "Authors": "['Sasaki, M.; Iida, S.; Hirata, Y.; Kusakabe, S.; Konishi, K.; Itakura, Y.; Tabata, K.; Kishimoto, M.; Kobayashi, H.; Ariizumi, T.; Intaruck, K.; Nobori, H.; Toba, S.; Sato, A.; Matsuno, K.; Yamagishi, J.; Suzuki, T.; Hall, W. W.; Orba, Y.; Sawa, H.']", "Abstract": "pulmonary infection with sars-cov-2 stimulates host immune responses and can also result in the progression of dysregulated and critical inflammation. throughout the pandemic, the management and treatment of covid-19 has been continuously updated with a range of antiviral drugs and immunomodulators. monotherapy with oral antivirals has proven to be effective in the treatment of covid-19. however, the treatment should be initiated in the early stages of infection to ensure beneficial therapeutic outcomes, and there is still room for further consideration on therapeutic strategies using antivirals. here, we show that the oral antiviral ensitrelvir combined with the anti-inflammatory corticosteroid methylprednisolone has higher therapeutic effects and better outcomes in a delayed dosing model of sars-cov-2 infected hamsters compared to the monotherapy with ensitrelvir or methylprednisolone alone. combination therapy with these drugs improved respiratory conditions and the development of pneumonia in hamsters even when the treatment was started after 2 days post infection. the combination therapy led to a differential histological and transcriptomic pattern in comparison to either of the monotherapies, with reduced lung damage and down-regulated expressions of genes involved in inflammatory response. furthermore, we found that the combination treatment is effective in infection with both highly pathogenic delta and circulating omicron variants. our results demonstrate the advantage of combination therapy with antiviral and corticosteroid drugs in covid-19 treatment. since both drugs are available as oral medications, this combination therapy could provide a clinical and potent therapeutic option for covid-19."}, {"Link/DOI": "https://doi.org/10.1101/2023.07.24.23293131", "Publication Date": "2023-12-27 00:00:00", "Title": "meta-analysis on plasmodium falciparum sulfadoxine-pyrimethamine resistance-conferring mutations in india identifies hot spots for genetic surveillance", "ID Score": "0.9999895", "Team Score": "0.84698164", "Authors": "['Sinha, A.; Kar, S.; Chauhan, C.; Yadav, C. P.; Kori, L.']", "Abstract": "backgroundindia is on track to eliminate malaria by 2030 but emerging resistance to the first-line antimalarials is a recognized threat. as artesunate+sulfadoxine-pyrimethamine (as+sp) is the drug-of-choice for uncomplicated p. falciparum malaria in most of india, it becomes evident to systematically monitor the validated mutations in pfdhfr and pfdhps genes across india. no systematic and robust countrywide surveillance has been reported for these parameters in india.  methodswe included studies that reported data on sp-resistance markers in p. falciparum across india from 2008. five major databases were exhaustively searched. individual and pooled prevalence estimates of mutations were obtained through random- and fixed-effect models. the study is registered with prospero (crd42021236012).  resultsa total of 37 publications with data from 80 districts, 21 states and 3 uts were included. the two pfdhfr mutations, c59r and s108n were the most prevalent mutations and appear to be stabilized/fixed. although rarest overall, the prevalence of i164l was observed to be as high as 32%. the pfdhfr double mutants were the most prevalent overall. the prevalence of triple and quadruple mutations was 6% and 5%, respectively which is an area of immediate concern. for pfdhps, the most prevalent mutation was a437g. for pfdhfr/pfdhps quintuple and sextuple mutations, it was observed that despite a low overall prevalence of these mutations, some areas are critical for surveillance.  conclusionthe analysis brings forward the sp-resistance hot spots and emphasizes critical gaps, and challenges, and suggests focal and local malaria genetic surveillance (including drug resistance markers) till malaria is eliminated.  key pointsthis manuscript concludes that currently used first-line drugs for p. falciparum malaria, particularly sulfadoxine-pyrimethamine, have a high likelihood of failing in near future. although currently effective, the evidence is backed by molecular meta-analyses data on drug resistance markers in india. the policy makers and program managers may use this robust data to decide whether it is time to change these currently used anti-malarials in india before it is too late. it also identifies certain hot spots for continuous genetic monitoring of the molecular markers for timely actions."}, {"Link/DOI": "https://doi.org/10.1101/2022.09.09.507373", "Publication Date": "2023-12-26 00:00:00", "Title": "does vaping increase the likelihood of sars-cov-2 infection? paradoxically yes and no", "ID Score": "0.99998975", "Team Score": "0.86813176", "Authors": "['Phandthong, R.; Wong, M.; Song, A.; Martinez, T.; Talbot, P.']", "Abstract": "data on the relationship between electronic cigarettes (ecs) and sars-cov-2 infection are limited and contradictory. evidence indicates that ec aerosols or nicotine increase ace2, sars-cov-2 virus receptors, which increase virus binding and susceptibility. our objectives were to determine if ec aerosols increased sars-cov-2 infection of human bronchial epithelial cells and to identify the causative chemical(s). a 3d organotypic model (epiairway) in conjunction with air liquid interface (ali) exposure was used to test the effects of aerosols produced from juul \"virginia tobacco\" and blu ecs, or individual chemicals (nicotine, propylene glycol, vegetable glycerin (pg/vg), and benzoic acid) on infection using sars-cov-2 pseudoparticles. exposure of epiairway to juul aerosols increased ace2, while blu and lab-made ec aerosols containing nicotine increased ace2 levels and tmprss2 activity, a spike protease that enables viral-cell fusion. pseudoparticle infection of epiairway increased with aerosols produced from pg/vg, pg/vg plus nicotine, or blu ecs. juul ec aerosols did not increase infection above controls. the baseline level of infection in juul treated aerosol groups was attributed to benzoic acid, which mitigated the enhanced infection caused by pg/vg or nicotine. the benzoic acid protection from enhanced infection continued at least 48 hours after exposure. tmprss2 activity was significantly correlated with e-liquid ph, which in turn was significantly correlated with infection, with lower ph blocking pg/vg and nicotine-induced-enhanced infection. while ace2 levels increased in epiairway tissues exposed to ec aerosols, infection depended on the ingredients of the e-liquids. pg/vg and nicotine enhanced infection, an effect that was mitigated by benzoic acid."}, {"Link/DOI": "https://doi.org/10.1101/2023.03.29.534747", "Publication Date": "2023-12-22 00:00:00", "Title": "novel mrna-based vp8* vaccines against rotavirus are highly immunogenic in rodents", "ID Score": "0.9999896", "Team Score": "0.934962", "Authors": "['Roier, S.; Prasad, V. M.; McNeal, M. M.; Lee, K. K.; Petsch, B.; Rauch, S.']", "Abstract": "despite the availability of live-attenuated oral vaccines, rotavirus remains a major cause of severe childhood diarrhea worldwide. due to the growing demand for parenteral rotavirus vaccines, we developed novel mrna-based vaccine candidates targeting the viral spike protein vp8*. our monomeric p2 (universal t cell epitope)-vp8* mrna design is equivalent to a protein vaccine currently in clinical development, while ls (lumazine synthase)-p2-vp8* was designed to form nanoparticles. cyro-electron microscopy and western blotting-based data presented here suggest that proteins derived from ls-p2-vp8* mrna are secreted in vitro and self-assemble into 60-mer nanoparticles displaying vp8*. mrna encoded vp8* was immunogenic in rodents and introduced both humoral and cellular responses. ls-p2-vp8* induced superior humoral responses to p2-vp8* in guinea pigs, both as monovalent and trivalent vaccines, with encouraging responses detected against the most prevalent p genotypes. overall, our data provide evidence that trivalent ls-p2-vp8* represents a promising mrna-based next-generation rotavirus vaccine candidate."}, {"Link/DOI": "https://doi.org/10.1101/2023.08.09.552716", "Publication Date": "2023-12-22 00:00:00", "Title": "the heme oxygenase-1 metalloporphyrin inhibitor stannsoporfin enhances the bactericidal activity of a novel regimen for multidrug-resistant tuberculosis in a murine model", "ID Score": "0.9778879", "Team Score": "0.9974131", "Authors": "['Ruelas Castillo, J.; Neupane, P.; Karanika, S.; Krug, S.; Quijada, D.; Garcia, A.; Ayeh, S.; Costa, D. L.; Sher, A.; Fotouhi, N.; Serbina, N.; Karakousis, P. C.']", "Abstract": "multidrug-resistant (mdr) mycobacterium tuberculosis (mtb) poses significant challenges to global tuberculosis (tb) control efforts. host-directed therapies (hdt) offer a novel approach for tb treatment by enhancing immune-mediated clearance of mtb. prior preclinical studies found that inhibition of heme oxygenase-1 (ho-1), an enzyme involved in heme metabolism, with tin-protoporphyrin ix (snpp) significantly reduced mouse lung bacillary burden when co-administered with the first-line antitubercular regimen. here we evaluated the adjunctive hdt activity of a novel ho-1 inhibitor, stannsoporfin (snmp), in combination with a novel mdr-tb regimen comprising a next-generation diarylquinoline, tbaj-876 (s), pretomanid (pa), and a new oxazolidinone, tbi-223 (o) (collectively, spao) in mtb-infected balb/c mice. after 4 weeks of treatment, spao + snmp 5 mg/kg reduced mean lung bacillary burden by an additional 0.69 log10 (p=0.01) relative to spao alone. as early as 2 weeks post-treatment initiation, snmp adjunctive therapy differentially altered the expression of pro-inflammatory cytokine genes, and cd38, a marker of m1 macrophages. next, we evaluated the sterilizing potential of snmp adjunctive therapy in a mouse model of microbiological relapse. after 6 weeks of treatment, spao + snmp 10 mg/kg reduced lung bacterial burdens to 0.71 {+/-} 0.23 log10 cfu, a 0.78 log-fold greater decrease in lung cfu compared to spao alone (p=0.005). however, adjunctive snmp did not reduce microbiological relapse rates after 5 or 6 weeks of treatment. snmp was well tolerated and did not significantly alter gross or histological lung pathology. snmp is a promising hdt candidate requiring further study in combination with regimens for drug-resistant tb."}]